CN1824664A - 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 - Google Patents
作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 Download PDFInfo
- Publication number
- CN1824664A CN1824664A CNA2006100068921A CN200610006892A CN1824664A CN 1824664 A CN1824664 A CN 1824664A CN A2006100068921 A CNA2006100068921 A CN A2006100068921A CN 200610006892 A CN200610006892 A CN 200610006892A CN 1824664 A CN1824664 A CN 1824664A
- Authority
- CN
- China
- Prior art keywords
- octane
- hydroxyl
- base
- nmr
- dmso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 71
- 150000008584 quinuclidines Chemical class 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 235
- -1 5,6,7,8-tetrahydronaphthalenyl Chemical group 0.000 claims abstract description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 201
- 229910052757 nitrogen Inorganic materials 0.000 claims description 197
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 196
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 112
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 105
- 229910052760 oxygen Inorganic materials 0.000 claims description 100
- 239000001301 oxygen Substances 0.000 claims description 100
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 91
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 76
- 238000002360 preparation method Methods 0.000 claims description 50
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 210000000621 bronchi Anatomy 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229950004288 tosilate Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 8
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 abstract description 3
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 abstract description 3
- 125000001624 naphthyl group Chemical group 0.000 abstract description 3
- 125000005842 heteroatom Chemical group 0.000 abstract description 2
- 125000006267 biphenyl group Chemical group 0.000 abstract 1
- 150000002390 heteroarenes Chemical class 0.000 abstract 1
- 239000002585 base Substances 0.000 description 245
- 238000000034 method Methods 0.000 description 180
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 75
- 239000000243 solution Substances 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- 150000002148 esters Chemical class 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 8
- 229940039748 oxalate Drugs 0.000 description 8
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 6
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000002026 chloroform extract Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000003551 muscarinic effect Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- RFHABUQANXJNQS-UHFFFAOYSA-N methyl 9h-xanthene-9-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)C3=CC=CC=C3OC2=C1 RFHABUQANXJNQS-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 2
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 208000012931 Urologic disease Diseases 0.000 description 2
- VSBFNCXKYIEYIS-UHFFFAOYSA-N Xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3OC2=C1 VSBFNCXKYIEYIS-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- KCTBOHUTRYYLJA-UHFFFAOYSA-N lithium;2h-furan-2-ide Chemical compound [Li+].C=1C=[C-]OC=1 KCTBOHUTRYYLJA-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- FSNYTEYOTCTPSO-SSDOTTSWSA-N (2r)-1-azabicyclo[2.2.2]octan-2-ol Chemical class C1CN2[C@H](O)CC1CC2 FSNYTEYOTCTPSO-SSDOTTSWSA-N 0.000 description 1
- FSNYTEYOTCTPSO-ZETCQYMHSA-N (2s)-1-azabicyclo[2.2.2]octan-2-ol Chemical compound C1CN2[C@@H](O)CC1CC2 FSNYTEYOTCTPSO-ZETCQYMHSA-N 0.000 description 1
- DSNGLKATJGBVIX-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ol Chemical compound C1CN2CCC1(O)C2 DSNGLKATJGBVIX-UHFFFAOYSA-N 0.000 description 1
- RQRSQXFVRUWISR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ol Chemical compound C1CN2CCC1(O)CC2 RQRSQXFVRUWISR-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- RRKMWVISRMWBAL-UHFFFAOYSA-N 3,4-dihydroxy-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(O)=C1O RRKMWVISRMWBAL-UHFFFAOYSA-N 0.000 description 1
- TXXJUGKQQAFZKH-UHFFFAOYSA-N 3-(2-phenylphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1C1=CC=CC=C1 TXXJUGKQQAFZKH-UHFFFAOYSA-N 0.000 description 1
- NIDWUZTTXGJFNN-UHFFFAOYSA-N 3-bromopropoxybenzene Chemical compound BrCCCOC1=CC=CC=C1 NIDWUZTTXGJFNN-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical class C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LUMNWCHHXDUKFI-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enylmethanol Chemical compound C1C2C(CO)CC1C=C2 LUMNWCHHXDUKFI-UHFFFAOYSA-N 0.000 description 1
- HAMMHSUBQYOIFQ-UHFFFAOYSA-N 9,10-dihydroanthracene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3CC2=C1 HAMMHSUBQYOIFQ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- RKWHSNUNUUMSBT-UHFFFAOYSA-N C(CC)(=O)OOC(=O)C1C2=CC=CC=C2CC=2C=CC=CC12 Chemical compound C(CC)(=O)OOC(=O)C1C2=CC=CC=C2CC=2C=CC=CC12 RKWHSNUNUUMSBT-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- OEXHQOGQTVQTAT-SSZRJXQFSA-N [(1r,5s)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)[N+]3(C)C(C)C)=CC=CC=C1 OEXHQOGQTVQTAT-SSZRJXQFSA-N 0.000 description 1
- YIOLGOWFHRDXOI-UHFFFAOYSA-N [Mg]C1=CC=CS1 Chemical compound [Mg]C1=CC=CS1 YIOLGOWFHRDXOI-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Abstract
一种式(I)的化合物,其中zC为苯环,包含一或多个杂原子的C4-C9杂芳族化合物或萘基、5,6,7,8-四氢萘基或联苯基;化合物对毒蕈碱性M3受体(Hm3)显示高亲和性。
Description
本申请是国际申请日为2000年7月7日(国际申请号为PCT/EP00/06469)、进入国家阶段申请号为00812754.9的题为“作为毒蕈碱性M3受体配体的奎宁环衍生物及其用途”的专利申请的分案申请。
技术领域
本发明涉及新的治疗学上有用的奎宁环衍生物,涉及一些用于它们的制备的方法和涉及包含它们的药用组合物。
本发明的新结构为具有强力和长效作用的抗毒蕈碱性药物。特别是这些化合物对毒蕈碱性M3受体(Hm3)显示高亲和性。
根据它们作为M3拮抗剂的性质,新化合物适用于治疗以下疾病:呼吸疾病例如慢性阻塞性肺病(COPD)、慢性支气管炎、支气管过敏反应、哮喘和鼻炎、泌尿性疾病例如尿失禁、神经缺乏性(neuripenia)尿频的尿频、神经原性或不稳定性膀胱、膀胱痉挛和慢性膀胱炎;和胃肠疾病例如应激性肠道综合征、痉挛性结肠炎、憩室炎和消化性溃疡。
这些要求保护的化合物也用于与β2激动剂、甾体、抗过敏药或磷酸二酯酶IV抑制剂一起治疗以上描述的有关的呼吸道疾病。
也可期望本发明化合物具有抗咳嗽性质。
依它们的性质而定,新化合物可适用于治疗迷走神经诱导的窦性心搏徐缓。
背景技术
在几篇专利中已描述作为抗痉挛和抗胆碱能药物的具有相关结构的化合物。
例如,在专利FR 2012964中描述下式的奎宁环醇(quinuclidinol)衍生物或其酸加成盐或季铵盐,
其中R为H、OH或具有1-4个碳原子的烷基,R1为苯基或噻吩基,且R2为环己基、环戊基或噻吩基,或当R为H时,R1和R2与它们连接的碳原子一起形成下式的三环基团,
其中X为-O-、-S-或-CH2-。
EP-418716描述下式的噻吩基羧酸酯
其中A为下面的基团
m和n=1或2
Q为-CH2-CH2-、-CH2-CH2-CH2-、-CH=CH-、
基团
Q’为=NR或NRR’基团,R1为任选取代的噻吩基、苯基、呋喃基、环戊基或环己基,R2为H、OH、C1-C4烷氧基或C1-C4烷基和Ra为H、F、Cl、CH3-或-NR。
US 5,654,314描述下式化合物,
其中R为任选卤代或羟基取代的C1-4烷基,R为C1-4烷基,或R和R’一起形成C4-6链烯基,X-为阴离子,且R1为H、OH、-CH2OH、C1-C4烷基或C1-C4烷氧基。
发明内容
本发明提供对毒蕈碱性M3受体具有强力拮抗活性的新的奎宁环衍生物,其具有式(I)中描述的化学结构,
其中:
为苯环,包含一或多个杂原子(优选选自氮、氧和硫原子)的C4-C9杂芳族基团或萘基、5,6,7,8-四氢萘基或联苯基;
R1、R2和R3每一个独立地表示氢或卤原子,或羟基,或苯基、-OR4、-SR4、-NR4R5、-NHCOR4、-CONR4R5、-CN、-NO2、-COOR4或-CF3基团,或为可由例如羟基或烷氧基任选取代的直链或分支低级烷基,其中R4和R5每一个独立表示氢原子、直链或分支低级烷基,或一起形成脂族环;或R1和R2一起形成芳族环、脂族环或杂环;
n为0-4的整数;
A表示-CH2-、-CH=CR6-、-CR6=CH-、-CR6R7-、-CO-、-O-、-S-、-S(O)-、SO2或-NR6-基团,其中R6和R7每一个独立表示氢原子、直链或分支低级烷基,或R6和R7一起形成脂族环;
m为0-8的整数,条件是当m=0时,A不为-CH2-;
p为1-2的整数且氮鎓双环上的取代可发生于2、3或4位,包括不对称碳的所有可能的构型;
B表示式i)或ii)的基团,
其中R10表示氢原子、羟基或甲基,且R8和R9每一个独立表示
其中R11表示氢或卤原子,或直链或分支低级烷基和Q表示单键、-CH2-、-CH2-CH2-、-O-、-O-CH2-、-S-、-S-CH2-或-CH=CH-,当i)或
ii)包含手性中心时,它们可表示两种构型中的任一的构型;
X表示一或多价酸的药学上可接受的阴离子。
在式(I)表示的本发明的季铵化合物中,等量阴离子(X-)与N原子的正电荷有关。X-可为多种无机酸的阴离子,例如氯化物、溴化物、碘化物、硫酸盐、硝酸盐、磷酸盐,和有机酸的阴离子,例如乙酸盐、马来酸盐、富马酸盐、枸橼酸盐、草酸盐、琥珀酸盐、酒石酸盐、苹果酸盐、扁桃酸盐、甲磺酸盐和对甲苯磺酸盐。X-优选为选自以下的阴离子,包括:氯化物、溴化物、碘化物、硫酸盐、硝酸盐、乙酸盐、马来酸盐、草酸盐或琥珀酸盐。X-更优选为氯化物、溴化物或三氟乙酸盐。
以上描述的式(I)表示的本发明化合物,可具有一或多个不对称碳,包括所有可能的立体异构体。单一异构体和异构体的混合物包括在本发明范围内。
如果R1至R7或R11中的任何一个表示烷基,优选所述烷基包含1-8个,优选1-6个且更优选1-4个碳原子。特别优选任何烷基由甲基、乙基、包括异丙基在内的丙基,包括正丁基、仲丁基和叔丁基在内的丁基表示。
所提及的与式(I)有关的脂族环和杂环优选包括3-10元,优选5-7元环。所提及的与以上式(I)有关的芳环优选包括6-14,优选6或10元环。
优选的式(I)化合物为那些其中表示如下基团的化合物,包括:苯基、吡咯基、噻吩基、呋喃基、联苯基、萘基、5,6,7,8-四氢萘基、苯并[1,3]二氧杂环戊基、咪唑基或苯并噻唑基,尤其是苯基、吡咯基或噻吩基;R1、R2和R3每一个独立表示氢或卤原子,或羟基、甲基、叔丁基、-CH2OH、3-羟基丙基、-OMe、-NMe2、-NHCOMe、-CONH2、-CN、-NO2、-COOMe或-CF3基团,特别为氢原子、羟基或卤原子,其中卤原子优选为氟,n=0或1,m为1-6的整数,特别是1、2或3,A表示-CH2-、-CH=CH-、-CO-、-NH-、-NMe-、-O-或-S-基团,特别是-CH2-、-CH=CH-或-O-基团。
也优选为p=2且连接于氮鎓双环[2.2.2]辛烷的取代基-OC(O)B处于3位,优选具有(R)构型。
进一步优选的式(I)化合物为那些其中B为如上定义的式i)或ii)基团的化合物,其中如果B为式(i)基团,那么R8和R9每一个独立表示苯基、2-噻吩基、3-噻吩基、2-呋喃基或3-呋喃基,其中R11为氢原子,且如果B为式(ii)基团,Q表示单键、-CH2-、-CH2-CH2-、-O-或-S-基团,特别为单键、-CH2-、-CH2-CH2-或-O-基团,最优选为单键或-O-基团;在任何情况下R10为氢原子或羟基或甲基,且当i)或ii)包含手性中心时,它们可表示(R)或(S)构型。
式(I)中的-OC(O)B基因最优选为二苯基乙酰氧基、2-羟基-2,2-二苯基-乙酰氧基、2,2-二苯基-丙酰氧基、2-羟基-2-苯基-2-噻吩-2-基-乙酰氧基、2-呋喃-2-基-2-羟基-2-苯基乙酰氧基、2,2-二噻吩-2-基乙酰氧基、2-羟基-2,2-二噻吩-2-基乙酰氧基、2-羟基-2,2-二噻吩-3-基乙酰氧基、9-羟基-9[H]-芴-9-羰氧基、9-甲基-9[H]-芴-9-羰氧基、9[H]-呫吨-9-羰氧基、9-羟基-9[H]-呫吨-9-羰氧基、9-甲基-9[H]-呫吨-9-羰氧基、2,2-双(4-氟苯基)-2-羟基乙酰氧基、2-羟基-2,2-二对甲苯基乙酰氧基、2,2-二呋喃-2-基-2-羟基乙酰氧基、2,2-二噻吩-2-基丙酰氧基、9,10-二氢蒽-9-羰氧基、9[H]-噻吨-9-羰氧基或5[H]-二苯并[a,d]环庚烯-5-羰氧基。特别优选的化合物为那些化合物,其中式(I)中的-OC(O)B基团为二苯基乙酰氧基、2-羟基-2,2-二苯基-乙酰氧基、2,2-二苯基-丙酰氧基、2-羟基-2-苯基-2-噻吩-2-基-乙酰氧基、2-呋喃-2-基-2-羟基-2-苯基乙酰氧基、2,2-二噻吩-2-基乙酰氧基、2-羟基-2,2-二噻吩-2-基乙酰氧基、2-羟基-2,2-二噻吩-3-基乙酰氧基、9-羟基-9[H]-芴-9-羰氧基、9-甲基-9[H]-芴-9-羰氧基、9[H]-呫吨-9-羰氧基、9-羟基-9[H]-呫吨-9-羰氧基或9-甲基-9[H]-呫吨-9-羰氧基。
最优选的式(I)化合物为那些化合物,其中氮鎓双环基团在氮原子上被以下基团取代,包括:3-苯氧基丙基、2-苯氧基乙基、3-苯基烯丙基、苯乙基、4-苯基丁基、3-苯基丙基、3-[2-羟基苯氧基]丙基、3-[4-氟苯氧基]丙基、2-苄氧基乙基、3-吡咯-1-基丙基、2-噻吩-2-基乙基、3-噻吩-2-基丙基、3-苯基氨基丙基、3-(甲基苯基氨基)丙基、3-苯硫基(sulfanyl)丙基、3-邻-甲苯氧基丙基、3-(2,4,6-三甲基苯氧基)丙基、3-(2-叔丁基-6-甲基苯氧基)丙基、3-(联苯-4-基氧基)丙基、3-(5,6,7,8-四氢萘-2-基氧基)丙基、3-(萘-2-基氧基)丙基、3-(萘-1-基氧基)丙基、3-(2-氟苯氧基)丙基、3-(2,4-二氟苯氧基)丙基、3-(3-三氟甲基苯氧基)丙基、3-(3-氰基苯氧基)丙基、3-(4-氰基苯氧基)丙基、3-(3-甲氧基苯氧基)丙基、3-(4-甲氧基苯氧基)丙基、3-(苯并[1,3]二氧杂环戊-5-基氧基)丙基、3-(2-氨基甲酰基苯氧基)丙基、3-(3-二甲基氨基苯氧基)丙基、3-(4-硝基苯氧基)丙基、3-(3-硝基苯氧基)丙基、3-(4-乙酰基氨基苯氧基)丙基、3-(3-甲氧基羰基苯氧基)丙基、3-[4-(3-羟基丙基)苯氧基]丙基、3-(2-羟基甲基苯氧基)丙基、3-(3-羟基甲基苯氧基)丙基、3-(4-羟基甲基苯氧基)丙基、3-(2-羟基苯氧基)丙基、3-(4-羟基苯氧基)丙基、3-(3-羟基苯氧基)丙基、4-氧代-4-噻吩-2-基丁基、3-(1-甲基-[1H]咪唑-2-基硫烷基)丙基、3-(苯并噻唑-2-基氧基)丙基、3-苄氧基丙基、6-(4-苯基丁氧基)己基、4-苯氧基丁基或2-苄氧基乙基。特别优选的化合物为那些化合物,其中氮鎓双环基团在氮原子上由以下基团取代,包括:3-苯氧基丙基、2-苯氧基乙基、3-苯基烯丙基、苯乙基、4-苯基丁基、3-苯基丙基、3-[2-羟基苯氧基]丙基、3-[4-氟苯氧基]丙基、2-苄氧基乙基、3-吡咯-1-基丙基、2-噻吩-2-基乙基或3-噻吩-2-基丙基。
以下化合物打算阐明(但不限制)本发明的范围。
3(R)-二苯基乙酰氧基-1-(3-苯氧基-丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-羟基-2,2-二苯基-乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2,2-二苯基丙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-羟基-2-苯基-2-噻吩-2-基-乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓-双环[2.2.2]辛烷;溴化物
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(3-苯氟基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-[3-(4-氟苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;氯化物
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(2-羟基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-吡咯-1-基丙基)-1-氮鎓-双环[2.2.2]辛烷;三氟乙酸盐
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-(2-苄氧基乙基)-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-(3-苯基烯丙基)-3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-羟基-9H-芴-9-羰氧基)-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-(4-苯基丁基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-(2-苯氧基乙基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-(3-苯氧基丙基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
1-苯乙基-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物3(R)-(9-羟基-9[H]-呫吨-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-羟基-9[H]-呫吨-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-(3-苯氧基-丙基)-1-氮鎓-双环[2.2.2]辛烷;溴化物
本发明也提供制备式(I)化合物的方法。
通过通式II烷基化试剂与通式III的化合物反应,可制备通式I的季铵衍生物。在通式I、II和III中,R1、R2、R3、、A、X、B、n、m和p如上定义。
通过以下描述的两个不同的实验方法a)和b),可进行该烷基化反应。在具体方法b)中提供一个新的实验方法,即应用平行制备多个化合物的固相提取方法学。在实验部分中描述方法a)和b)。通过按照标准方法,经合成制备市场上不能得到的通式II化合物。例如,通过相应的芳族衍生物或其钾盐与通式Y-(CH2)m-X的烷基化试剂反应,
其中X可为卤素且Y可为卤素或磺酸酯,可得到其中n=0和A=-O-、-S-或-NR6的化合物,其中R6如上定义。在其它的实例中,经已知方法从相应的通式IV的醇衍生物合成其中n>=1的通式II化合物。
通过在以下流程中阐明的和在实验部分中详述的三种不同的方法c、d和e,可制备通式III化合物。
通过与相应的有机金属衍生物反应,从通式VII的二羟乙酸酯也可制备一些通式III化合物,
其中B为式i)的基团,R8和R9如上所述和R10为羟基。
按照以上描述的和在实验部分中详述的标准方法c、d和e,从相应的二羟乙酸可制备通式VII化合物。其中R8为2-噻吩基或2-呋喃基的式VII的二羟乙酸酯衍生物先前未见描述。
以下化合物为先前未见描述的通式III和VII化合物的实例:9-甲基-9[H]-芴-9-羧酸1-氮杂双环[2.2.2]辛-3(R)-基酯(中间体I-1c);9-甲基-9[H]-呫吨-9-羧酸1-氮杂双环[2.2.2]辛-3(R)-基酯(中间体I-1d);
2-羟基二噻吩-2-基-乙酸1-氮杂双环[2.2.2]辛-4-基酯(中间体I-4a);氧代噻吩-2-基-乙酸1-氮杂双环[2.2.2]辛-4-基酯(中间体I-4b);氧代噻吩-2-基-乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯(中间体I-4g);氧代呋喃-2-基-乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯(中间体I-4e);
2-羟基-2,2-二呋喃-2-基-乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯(中间I-4d)。
式V化合物可以是:
在WO 150080中描述的4-羟基-1-氮杂双环[2.2.1]庚烷
在Grob,C.A.等Helv.Chim.Acta(1958),41,1184-1190中描述的4-羟基-1-氮杂双环[2.2.2]辛烷
在Ringdahl,R.Acta Pharm Suec.(1979),16,281-283中描述的并可从CU Chemie Uetikon GmbH市售得到的3(R)-羟基-1-氮杂双环[2.2.2]辛烷或3(S)-羟基-1-氮杂双环[2.2.2]辛烷。
具体实施方式
以下实施例打算阐明(但不限于)以上已描述的实验方法。
经1H-NMR和MS证实所制备的化合物结构。使用Varian 300MHz仪器记录NMR且化学位移表达为从内标物四甲基硅烷的百万分之一(δ)。使用Waters仪器上的反相层析法,经HPLC测定它们的纯度,伴随得到大于95%的值。在Hewlctt Packard仪器上经电子轰击电离质谱得到分子离子。
方法-a-
实施例20-3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷,溴化物的制备。
将200mg(呋喃-2-基)-羟基-苯基乙酸1-氮杂-双环[2.2.2]辛-3(R)-基酯(0.6mmol)悬浮于4ml的CH3CN和6ml的CHCl3中。向该悬浮液中加入0.48ml(3mmol)的3-苯氧基丙基溴。在惰性气氛中,于室温下搅拌72h后,蒸发溶剂。加入乙醚并搅拌混合物。过滤得到的固体,用乙醚洗涤几次。得到为非对映体混合物的标题化合物0.27g(83%)。
1H-NMR(DMSO-d6):δ1.50-2.20(m,6H),2.25(m,1H),3.10(m,1H),3.20-3.60(m,6H),3.95(m,1H),4.05(m,2H),5.20(m,1H),6.25-6.35(双dd,1H),6.45(m,1H),6.95(m,4H),7.30-7.50(m,7H),7.70(m,1H);MS[M-Br]+:462;mp 166℃。
方法-b-
实施例51-3(R)-(2-羟基-2,2-二-噻吩-2-基乙酰氧基)-1-[3-(萘-1-基氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐的制备.
将60mg(0.17mmols)的羟基-二噻吩-2-基乙酸1-氮杂-双环[2.2.2]辛-3(R)-基酯溶于1ml的dmso中。向该溶液中加入188mg(0.85mmol)的3-(萘-1-基氧基)-丙基氯。在室温下搅拌过夜后,经用阳离子交换Mega Bond Elut柱(cartridge)进行固相提取纯化该混合物,该筒预先用0.1M NaH2PO4缓冲液调节在pH=7.5。把反应混合物应用到柱上,首先用2ml的DMSO洗涤,然后用5ml的CH3CN洗涤三次,冲洗掉所有的原料。用5ml在CH3CN∶CHCl3(2∶1)中的0.03M TFA溶液洗脱铵衍生物。用300mg聚(4-乙烯基吡啶)中和该溶液,过滤,蒸发至干。
得到17mg(15%)的标题化合物。1H-NMR(DMSO-d6):δ1.7-2.1(m,4H),2.2-2.4(m,3H),3.2-3.6(m,7H),4.0(m,1H),4.2(t,2H),5.25(m,1H),7.0(m,3H),7.2(m,2H),7.4-7.6(m,7H),7.85(d,1H),8.2(d,1H);MS[M-CF3COO]+:534。
方法-c-
通过标准酯化方法,从相应的羧酸或按照在实施例I-1e、I-1f和I-1g中描述的方法或按照在文献:FR2012964;larsson.L等.ActaPharm.Suec.(1974),11(3),304-308;Nyberg,K.等.Acta Chem.Scand.(1970),24,1590-1596;和Cohen,V.I.等.J.Pharm.Sciences(1992),81,326-329中描述的方法,制备通式VI的甲基酯衍生物。
实施例I-1a-(呋喃-2-基)羟基苯基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
将3.24g(0.014mols)的(呋喃-2-基)-羟基-苯基乙酸甲酯溶于85ml甲苯中。向该溶液中加入2.08g(0.016mols)的3-(R)-羟基-1-氮杂双环[2.2.2]辛烷和0.224g(5.6mmols)的HNa(60%悬浮于矿物油中)。伴随连续除去馏出液,将混合物回流,必要时用新鲜甲苯替换1.5小时。用2N HCl酸提取冷却的混合物,用乙酸乙酯洗涤水层,用K2CO3碱化且用CHCl3提取。经Na2SO4干燥有机层,蒸发。在室温下冷却后,使所得到的油(3.47g)结晶。将该固体悬浮于己烷中,过滤。得到为2.5g(54%)的非对映异构体的混合物,140-142℃;GC/MS[M]+:327;
1H-NMR(CDCl3):δ1.20-1.70(m,4H),1.90-2.10(m,1H),2.45-2.80(m,5H),3.10-3.30(m,1H),4.8(bs,OH),4.90-5.0(m,1H),6.20(m,1H),6.35(m,1H),7.30-7.50(m,4H),7.60-7.70(m,2H)。
在从沸腾的乙腈中使0.5g该混合物结晶四次后,得到0.110g纯的非对映体(1)。从结晶母液中得到另一种非对映体(2)。(*:构型未指定)。将非对映体1水解,得到为纯的对映体的(+)-2-羟基-2-苯基-2-呋喃-2-基乙酸,[α]25 D=+5.6(c=2,EtOH)。将非对映体2水解,得到为纯的对映体的(-)-2-羟基-2-苯基-2-呋喃-2-基乙酸,[α]25 D=-5.7(c=2,EtOH)。
非对映体1:2(*)-(呋喃-2-基)羟基苯基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯.1H-NMR(CDCl3):δ1.20-1.70(m,4H),1.90(m,1H),2.45-2.50(m,1H),2.50-2.80(m,4H),3.10-3.20(m,1H),4.8(bs,OH),4.90-5.0(m,1H),6.20(m,1H),6.35(m,1H),7.30-7.50(m,4H),7.60-7.70(m,2H)。非对映体2:2(*)-(呋喃-2-基)羟基苯基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯.1H-NMR(CDCl3):δ1.20-1.70(m,4H),2.10(m,1H),2.50-2.80(m,5H),3.20-3.30(m,1H),4.8(bs,OH),4.90-5.0(m,1H),6.20(m,1H),6.35(m,1H),7.30-7.50(m,4H),7.60-7.70(m,2H)。
实施例I-1b-呋喃-2-基羟基噻吩-2-基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
如在实施例I-1a中那样制备。得到3.06g(64.3%)的非对映异构体的混合物,mp:172℃;GC/MS[M]+:333;v1H-NMR(DMSO-d6):δ1.21-1.27(m,1H),1.41-1.60(m,3H),1.87(m,1H),2.36-2.69(m,5H),3.02-3.14(m,1H),4.75-4.82(m,1H),6.24-6.25(m,1H),6.42-6.45(m,1H),7.01-7.06(m,1H),7.11-7.14(m,2H),7.51-7.54(m,1H),7.66-7.69(m,1H)。
实施例I-1c-9-甲基-9[H]-芴-9-羧酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
如在实施例I-1a中那样制备。得到3.34g油(80%)。通过形成草酸盐(1∶1)将该产物固化,mp:186℃;MS[M游离碱+1]+:334。草酸盐,1H-NMR(DMSO-d6):δ1.43-1.55(m,2H),1.68-1.78(m,2H),1.75(s,3H),2.02(m,1H),2.70-2.90(m,1H),2.92-3.15(m,4H),3.50-3.57(m,1H),4.88(m,1H),7.35-7.47(m,4H),7.62-7.70(m,2H),7.89-7.91(m,2H)。
实施例I-1d-9-甲基-9[H]-呫吨-9-羧酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
如在实施例I-1a中那样制备。得到1.91g油(53%)。通过形成草酸盐(1∶1)将该产物固化,mp:152℃;MS[M游离碱+1]+:350。草酸盐,1H-NMR(DMSO-d6):δ1.20-1.30(m,1H),1.40-1.52(m,1H),1.64-1.81(m,2H),1.90(s,3H),2.0(m,1H),2.53-2.66(m,1H),2.71-2.76(m,1H),2.97-3.10(m,3H),3.44-3.52(m,1H),4.90-4.92(m,1H),7.12-7.18(m,4H),7.32-7.38(m,2H),7.43-7.48(m,2H),8.0-9.8(bs,1H,H+)。
实施例I-1e-9-甲基-9[H]-芴-9-羧酸甲酯的制备.
在N2气氛下,于0和5℃之间,将二异丙基氨化锂(26.7ml在庚烷/四氢呋喃/乙基苯中的2M溶液,0.053mol)加入到搅拌着的9[H]-芴-9-羧酸(5g,0.0237mol)在THF(70ml)中的溶液中。把混合物温热至室温并回流1.5小时。将反应混合物冷却至室温,加入CH3I(1.85ml,0.03mol)在THF(1.85ml)中的溶液。在室温下,搅拌混合物过夜且蒸发。向在MeOH(70ml)中的残余物中加入在甲醇(25ml)中的浓硫酸(3.9ml),回流混合物2小时并蒸发。在氯仿和饱和K2CO3溶液之间分配残余物。用氯仿再次提取水层,合并有机层,用水洗涤,经硫酸镁干燥,蒸发至干,得到5.73g棕色的油。经柱层析法(硅胶,己烷/乙酸乙酯95∶5)纯化该产物,得到4.43g(78.5%)的纯产物,结构经1H-NMR证实。
1H-NMR(CDCl3):δ1.80(s,3H),3.60(s,3H),7.50-7.65(m,4H),7.75(m,2H),8.0(m,2H)。
实施例I-1f-9-甲基-9[H]-呫吨-9-羧酸甲酯的制备.
如在实施例I-1e中那样制备。得到2.65g(47.2%)。
1H-NMR(CDCl3):δ1.90(s,3H),3.6(s,3H),7.05-7.35(m,8H)。
实施例I-1g-9-羟基-9[H]-呫吨-9-羧酸甲酯的制备.
在N2气氛下,于0和5℃之间,将二异丙基氨化锂(20.3ml的2M在庚烷/四氢呋喃/乙基苯中的溶液,0.041mol)加入到搅拌着的7g(0.029mol)的9[H]-呫吨-9-羧酸甲酯(通过标准方法制备)在THF(70ml)中的溶液中。在该温度下,搅拌混合物1小时,然后在0℃下通过N2压力加入到氧在乙醚中的干燥溶液中。30分钟后,加入等体积的NaHSO3(40%)水溶液,并把反应混合物温热至室温,搅拌30分钟。分离两层并用乙酸乙酯提取水相两次。合并有机相,用NaHSO3(40%水溶液)处理,用水洗涤,经硫酸钠干燥,蒸发至干,得到8.89g棕色的固体。
用5g原料重复该方法,得到6.04g相同的棕色固体。
把产物合并,经柱层析法(硅胶,己烷/乙酸乙酯,90∶10)纯化,得到7.60g(球形Rt,59.4%)的纯产物,结构经1H-NMR证实。
1H-NMR(DMSO-d6):δ3.5(s,3H),7.0(s,1H,OH),7.2(m,4H),7.4(m,2H),7.55(m,2H)。
方法-d-
实施例I-2a-10,11-二氢-5[H]-二苯并[a,d]环庚烷-5-羧酸1-氮杂双环[2.2.2]辛-3-(R)-基酯的制备.
将2.15g的10,11-二氢-5[H]-二苯并[a,d]环庚烷-5-羧酸(9.0mmol)溶于40ml的CHCl3(不含乙醇)中。在0℃下,把溶液冷却并加入0.86ml草酰氯(9.9mmols)和1滴DMF。搅拌混合物并使之温热至室温。在该温度下]小时后,蒸发溶剂,并把残余物溶于CHCl3中且再次蒸发。把该方法重复两次。将所得到的油溶于20ml甲苯中,并加入到1.26g(9.9mmol)的3-(R)-羟基-1-氮杂双环[2.2.2]辛烷在40ml热的甲苯中的溶液中。回流反应混合物2小时。冷却后,用2N HCl酸提取混合物。用K2CO3碱化水层,用CHCl3提取。经Na2SO4干燥有机层,蒸发至干。经柱层析法(硅胶,CHCl3∶MeOH∶NH4OH,95∶5∶0.5)纯化残余物。得到1.5g(48%);mp:112-113℃;CG/MS[M]-:347;
1H-NMR(CDCl3):δ1.10-1.35(m,2H),1.40-1.52(m,1H),1.52-1.68(m,1H),1.90(m,1H),2.40-2.60(m,2H),2.60-2.77(m,3H),2.83-2.96(m,2H),3.07-3.19(m,1H),3.25-3.40(m,2H),4.80(m,2H),7.10-7.30(m,8H)。如在Kumazawa T.等,J.Med.Chem.,(1994),37,804-810中描述的那样,制备10,11-二氢-5[H]-二苯并[a,d]环庚烷-5-羧酸。
实施例I-2b-5[H]-二苯并[a,d]环庚烯-5-羧酸1-氮杂双环[2.2.2]辛-3-(R)-基酯的制备.
如在实施例I-2a中那样制备。得到3.12g(71%);mp 129℃;MS[M+1]+:346;1H-MR(DMSO-d6):δ0.90-1.10(m,2H),1.30-1.50(m,2H),1.58(m,1H),2.21-2.26(m,2H),2.47-2.50(m,3H),2.86-2.94(m,1H),4.48-4.51(m,1H),5.33(s,1H),7.0(m,2H),7.29-7.43(m,6H),7.49-7.51(m,2H)。
如在M.A.Davis等,J.Med.Chem.,(1964),Vol 7,88-94中描述的那样,制备5[H]-二苯并[a,d]环庚烯-5-羧酸。
实施例I-2c-9,10-二氢蒽-9-羧酸1-氮杂双环[2.2.2]辛-3-(R)-基酯的制备.
如在实施例I-2a中那样制备。得到0.77g(62.6%);mp 139℃;MS[M+1]+:334;1H-NMR(DMSO-d6):δ1.1-1.2(m,1H),1.25-1.40(m,2H),1.40-1.55(m,1H),1.73(m,1H),2.20(m,1H),2.35-2.65(m,4H),2.90-2.98(m,1H),3.93-4.14(dd,2H,J=1.8Hz,J=4.3Hz),4.56(m,1H),5.14(s,1H),7.25-7.35(m,4H),7.35-7.50(m,4H)。
如在E.L.May和E.Mossettig;J.Am.Chem.Soc.,(1948),Vol 70,1077-9中描述的那样,制备9,10-二氢-蒽-9-羧酸。
方法-e-
实施例I-32,2-二苯基丙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
将1.1g(4.8mmol)的2,2-二苯基丙酸溶于20ml的THF中。向该溶液中加入0.87g(5.3mmol)的1,1’-羰基二咪唑并回流混合物1小时。在形成imidazolide后,经TLC监控反应。当反应完成时,蒸发溶剂部分,加入0.67g(5.3mmol)的3-(R)-羟基-1-氮杂双环[2.2.2]辛烷。回流反应混合物16h,冷却,用乙醚稀释并用水洗涤。用HCl 2N提取有机层,用K2CO3碱化酸溶液,并用CHCl3提取。经Na2SO4干燥有机溶液,蒸发至干,得到1.21g(75.2%)油,其被鉴定为标题酯。
将0.64g(1.9mmol)的2,2-二苯基丙酸1-氮杂双环[2.2.2]辛-3(R)-基酯溶于6ml酮中,并加入0.085g(0.95mmol)的草酸。在缓慢加入乙醚后,形成白色固体。得到0.33g(45.6%)的2,2-二苯基-丙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的草酸盐;mp:146℃;MS[M游离碱+1]+:336。
草酸盐,1H-NMR(CDCl3):δ1.40-1.64(m,2H),1.90(s,3H),1.80-2.0(m,2H),2.31(m,1H),2.73-2.85(m,1H),3.0-3.10(m,1H),3.10-3.32(m,3H),3.53-3.70(m,1H),5.13(m,1H),7.14-7.40(m,10H),9.25(宽带,2H,H+)。
方法-f-
实施例I-4a-2-羟基-2,2--二噻吩-2-基乙酸1-氮杂双环[2.2.2]辛-4-基酯的制备.
从在15ml的THF中的220mg(9mmols)的镁和0.86ml(9mmols)的2-溴代噻吩,制备溴化2-噻吩基镁的溶液。把该溶液加入到溶于20ml的THF中的1.95g(7mmols)的氧代噻吩-2-基-乙酸1-氮杂双环[2.2.2]辛-4-基酯(中间体1-4b)中。在室温下,搅拌混合物1小时,回流1小时,冷却,用饱和氯化铵溶液处理,并用乙醚提取。除去溶剂后,把得到的固体从乙腈中重结晶,得到1.45g白色固体(56%)。
1H-NMR(DMSO-d6):δ1.80-2.0(m,6H),2.80-3.0(m,6H),7.0(m,2H),7.13(m,2H),7.18(s,1H),7.51(m,2H);MS[M+1]:350;mp:174℃。
实施例I-4b-氧代噻吩-2-基-乙酸1-氮杂双环[2.2.2]辛-4-基酯的制备.
在0℃下,将草酰氯(1.5ml,0.017mol)加入到氧代噻吩-2-基-乙酸(2.24g,0.014mol)和二甲基甲酰胺(1滴)在30ml的氯仿(不含乙醇)中的溶液中。搅拌混合物并使之在室温下温热。1小时后,蒸发溶剂。把残余物溶于氯仿中,再次蒸发。将该方法重复两次。把得到的产物溶于CHCl3(30ml)中并在70℃下加入到1.1g(0.009mols)的4-羟基-1-氮杂双环[2.2.2]辛烷、1.8ml的三乙胺(0.013mols)、0.6g(0.9mmols)的N-(甲基聚苯乙烯)-4-(甲基氨基)吡啶的悬浮液中。回流混合物1小时,冷却,过滤,用水洗涤。用稀HCl溶液提取标题产物,用CHCl3洗涤,用K2CO3碱化,并用CHCl3再次提取。除去溶剂后,得到1.47g(45%)的固体。1H-NMR(dmso):δ2.0(m,6H),2.9(m,6H),7.35(m,1H),8.05(m,1H),8.3(m,1H)。
实施例I-4c-(呋喃-2-基)羟基苯基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
在-70℃、于氮气氛下,将溴化苯基镁0.0057mol(5.7ml的1M溶液在THF中)加入到15ml THF中的1.3g(0.0052mol)的氧代呋喃-2-基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯(中间体I-4e-)溶液中。在该温度下搅拌混合物10分钟,然后温热至室温。1小时后,用饱和氯化铵溶液处理反应混合物,用乙酸乙酯提取三次。合并有机相,用水洗涤,经Na2SO4干燥。除去溶剂后,用乙醚处理得到的固体,过滤,得到0.67g(40%)的产物,经1H-NMR证实其结构。如在实施例I-1a(方法C)中描述的那样,也制备该化合物。经从乙腈中结晶分离非对映体并经1H-NMR鉴别。
实施例I-4d-2-羟基-2,2-二呋喃-2-基-乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
如在实施例I-4c中那样,从中间体I-4e-和2-呋喃基锂合成标题化合物,按照标准方法,用呋喃和丁基锂制备2-呋喃基锂。得量为380mg(8%)。1H-NMR(CDCl3):δ1.2-1.4(m,1H),1.4-1.8(m,3H),2.0(m,1H),2.6-2.85(m,5H),3.2(m,1H),5.0(m,1H),6.4(m,3H),7.3(m,1H),7.5(m,2H)。MS[M+1]+:318。
实施例I-4e-氧代呋喃-2-基-乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
在0℃下,将草酰氟(9.75ml,0.112mol)加入到氧代呋喃-2-基乙酸(10g,0.071mol)和二甲基甲酰胺(1滴)在150ml的氯仿(不含乙醇)中的溶液中。搅拌混合物并使之在室温下温热。5小时后,蒸发溶剂。把残余物溶于氯仿中,再次蒸发。将该方法重复两次。把得到的产物溶于CHCl3(150ml)中并在0℃下向其中加入3(R)-奎宁环醇(10.90g,0.086mol)在CHCl3(150ml)中的溶液。搅拌混合物并使之在室温下温热。在室温下15h后,用10%碳酸钾水溶液洗涤混合物,然后用水洗涤,经Na2SO4干燥,蒸发,得到为深色油的标题化合物9.34g(52.5%)。经NMR证实结构。
1H-NMR(CDCl3):δ1.40-1.60(m,1H),1.60-1.80(m,2H),1.80-2.05(m,1H),2.20(m,1H),2.70-3.10(m,5H),3.30-3.45(m,1H),5.10(m,1H),6.7(m,1H),7.7(m,1H),7.8(m,1H)。
实施例I-4f-2-羟基-2-苯基-2-噻吩-2-基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
如在实施例I-4c中所述,从中间体I-4g制备标题化合物。得到3g(33%)为非对映体的混合物。在将1.5g的该混合物从沸腾的异丙醇中结晶5次后,得到0.200g纯的非对映体(1)。从第一份结晶母液中富集另一种非对映体(2)。将非对映体(1)水解,得到为纯的对映体的(+)-2-羟基-2-苯基-2-噻吩-2-基乙酸,[α]25 D=+25.4(c=2,EtOH)。该值指定为R构型,条件是在文献(A.I.Meyers等.J.Org.Chem.(1980),45(14),2913)中,2(S)对映体已被描述具有[α]25 D=-20(c=2,EtOH)。非对映体1:2(R)-2-羟基-2-苯基-2-噻吩-2-基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯1H-NMR(DMSO-d6):δ1.1-1.25(m,1H),1.3-1.6(m,3H),1.83(m,1H),2.4-2.7(m,5H),3.1(m,1H),4.8(m,1H),7.0(m,2H),7.05(m,1H),7.3-7.4(m,3H),7.4-7.45(m,2H),7.5(m,1H)。
非对映体2:2(S)-2-羟基-2-苯基-2-噻吩-2-基乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯1H-NMR(DMSO-d6):δ1.1-1.25(m,1H),1.4-1.6(m,3H),1.9(m,1H),2.3-2.7(m,5H),3.05(m,1H),4.8(m,1H),7.0(m,2H),7.05(m,1H),7.3-7.4(m,3H),7.4-7.45(m,2H),7.5(m,1H)。
实施例I-4g-氧代噻吩-2-基-乙酸1-氮杂双环[2.2.2]辛-3(R)-基酯的制备.
在0℃下,将草酰氯(1.34ml,0.0154mol)加入到氧代噻吩-2-基-乙酸(2g,0.0128mol)和二甲基甲酰胺(1滴)在30ml氯仿(不含乙醇)中的溶液中。搅拌混合物并使之在室温下温热。1小时后,蒸发溶剂。将残余物溶于氯仿中,再次蒸发。把该方法重复两次。将得到的产物溶于CHCl3(30ml)中,并在0℃下向其中加入3(R)-奎宁醇(1.95g,0.0154mol)在CHCl3(30ml)中的溶液。搅拌混合物并使之在室温下温热。在室温下1.5h后,用10%碳酸钾水溶液洗涤该混合物,然后用水洗涤,经Na2SO4干燥,蒸发,得到3.14g(92.6%)为黄色油的标题化合物。1H-NMR(CDCl3):δ1.40-1.50(m,1H),1.50-1.70(m,1H),1.70-1.80(m,1H),1.90-2.0(m,1H),2.15(m,1H),2.70-3.05(m,5H),3.30-3.40(m,1H),5.05(m,1H),7.20(m,1H),7.85(m,1H),8.10(m,1H)。
如在以下参考文献中描述的那样,可制备式B-C(O)OH的其它羧酸,它们在方法c、d、e或在实施例I-1e、I-1f和I-1g中尚未描述其制备(或它们的衍生物甲酯、氯化物或imidazolide的合成),且其在市场上是不能得到的。
FR 2012964
M.A.Davis等;J.Med.Chem.(1963),6,513-516.
T.Kumazawa等;J.Med.Chem.(1994),37(6),804-810.
M.A.Davis等:J.Med.Che m.(1964),第(7)卷,88-94.
Sestanj,K;Can.J.Chem.,(1971),49,664-665.
Burtner,R.;J.Am.Chem.Soc.,(1943),65,1582-1585
Heacock R.A.等;Ann.Appl.Biol.,(1958),46(3),352-365.
Rigaudy J.等;Bull.Soc.Chim.Franee,(1959),638-43.
Ueda I.等;Bull.Chem.Soc.Jpn;(1975),48(8),2306-2309.
E.L.May等;J.Am.Chem.Soc.,(1948),70,1077-9.
药用组合物也包括在本发明范围内,组合物包含与药学上可接受的载体或稀释剂混合的作为活性成分的至少一种通式(I)奎宁环衍生物。优选以适于口服给药的形式制备组合物。
可与一种或多种活性化合物混合以形成本发明组合物的药学上可接受的载体或稀释剂为本领域所熟知的且所使用的实际赋形剂特别依组合物预定的给药方法而定。
本发明组合物优选适用于口服给药。在这种情况下,用于口服给药的组合物可采用片剂、簿膜包衣片剂、液体吸入剂、粉末吸入剂和吸入气溶胶的形式,所有形式包含一或多种本发明化合物;通过本领域熟知的方法可制备这样的制剂。
可用于组合物制备的稀释剂包括那些液体和固体稀释剂,如果需要,其与同着色剂和矫味剂一起的活性成分相适配。片剂或簿膜包衣片剂可便利地包含500-1mg,优选5-300mg的活性成分。吸入组合物可包含1μg-1,000μg,优选10-800μg的活性成分。在人的治疗中,通式(I)化合物的剂量依治疗所需的作用和治疗的持续时间而定;成人剂量一般每天为3mg-300mg片剂和为每天10μg-800μg吸入组合物。
药理作用
以下实施例证实本发明化合物的优良药理活性。如以下描述的那样,得到人毒蕈碱性受体结合及豚鼠支气管痉挛试验中的结果。
人毒蕈碱性受体研究
按照Waelbroek等(1990)(1)的方法,进行[3H]-NMS对人毒蕈碱性受体的结合。在25℃下进行试验。使用来自表达人毒蕈碱性受体Hm3的基因的稳定转染的中国仓鼠卵巢-K1细胞(CHO)的膜制备液。
为测定IC50,将膜制备液悬浮于DPBS中以达到Hm3亚型的最终浓度89μg/ml。将膜悬浮液与含氚化合物一起孵育60分钟。孵育后,经过滤分离膜部分并测定结合的放射活性。经加入10-4M阿托品测定非特异性结合。重复测定至少6个浓度以生成各自的置换(displacement)曲线。
化合物号 | 对受体M3的结合(IC50nM) |
阿托品 | 3.2 |
IPRATROPIUM | 3.0 |
1 | 31 |
2 | 15 |
7 | 22 |
8 | 4.8 |
17 | 14 |
18 | 6.6 |
20 | 6.8 |
35 | 13 |
36 | 2.7 |
39 | 3.8 |
44 | 4.4 |
53 | 5.6 |
71 | 8.2 |
74 | 16 |
77 | 3.1 |
78 | 5 |
84 | 9.9 |
89 | 5.4 |
99 | 31 |
100 | 14 |
101 | 7.6 |
109 | 31 |
114 | 14 |
116 | 23 |
126 | 13 |
127 | 16 |
128 | 8.8 |
129 | 6.3 |
136 | 11 |
137 | 6.9 |
138 | 19 |
146 | 13 |
(1)M.Waelbroek,M.Tastenoy,J.Camus,J Christophe.选择性拮抗剂对大鼠前脑四种毒蕈碱性受体(M1-M4)的结合.Mol.Pharmacol.(1990)38:267-273
我们的结果显示本发明化合物对M3受体具有亲和性,其与参比化合物非常相似。
本发明的化合物优选对毒蕈碱性M3受体(HM3),优选对人毒蕈碱性受体具有高亲和性。经例如以上描述的体外试验一般能够测量亲和水平。
本发明的优选化合物对M3受体具有低于35,优选低于25、20或15,更优选低于10、8或5的IC50(nM)。豚鼠支气管痉挛试验
按照Konzett和Rssler(2)的方法,进行研究。将受试药物的等分试样溶液雾化且由麻醉通风换气使雄性豚鼠(Dunkin-Hartley)吸入。给药前和给药后及几个时间点的肺气道阻力的百分比变化,测定支气管对静脉乙酰胆碱攻击的应答。
2.Konzett H.,Rssler F.Versuchsanordnung zu Untersuchungen anderbronchialmuskulatur.Arch.Exp.Path.Pharmaco1.195,71-74(1940)
本发明的化合物抑制对乙酰胆碱的支气管痉挛应答,具有高效和长效作用。
从以上描述的结果,本领域的普通技术人员能够易于理解本发明化合物具有优良的抗毒蕈碱性活性(M3),因此可用于治疗其中涉及毒蕈碱性M3受体的疾病,包括:呼吸疾病例如慢性阻塞性肺病、慢性支气管炎、哮喘和鼻炎、泌尿性疾病例如尿失禁和神经缺乏性尿频中的尿频、神经原性膀胱、夜间遗尿症、不稳定性膀胱、膀胱痉挛和慢性膀胱炎及胃肠道疾病例如应激性肠道综合征、痉挛性结肠炎和憩室炎。
本发明另外提供式(I)化合物或药学上可接受的组合物,组合物包含用于经疗法治疗人或动物体特别是治疗呼吸、泌尿或胃肠道疾病的方法的式(I)化合物。
本发明另外提供式(I)化合物或药学上可接受的组合物的用途,用途包括式(I)化合物用于制备治疗呼吸、泌尿或胃肠道疾病的药物。
另外,式(I)化合物和包含式(I)化合物的药用组合物可用于治疗呼吸、泌尿或胃肠道疾病的方法,该方法包括给予需要这样治疗的人或动物患者有效量的式(I)化合物或包含式(I)化合物的药用组合物。
通过以下实施例将进一步阐明本发明。实施例仅作为说明给出并不构成一种限制。
实施例1
3(R)-二苯基乙酰氧基-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a合成标题化合物。最终步骤的产量为500mg,81%。1H-NMR(CDCl3):δ1.72-2.18(m,6H),2.35(m,1H),3.0(m,1H),3.23(m,1H),3.59-3.88(m,5H),4.0(m,2H),4.30(m,1H),5.1(s,1H),5.25(m,1H),6.8-6.9(m,2H),6.9-7.0(m,1H),7.2-7.4(m,12H);MS[M-Br]-:456;mp 129℃。
实施例2
3(R)-(2-羟基-2,2-二苯基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a合成标题化合物。最终步骤的产量为280mg,42%。1H-NMR(DMSO-d6):δ1.5-1.7(m,2H),1.9-2.1(m,4H),2.3(m,1H),3.1(m,1H),3.2-3.5(m,6H),3.9-4.1(m,3H),5.25(m,1H),6.8(bs,OH),6.95(m,3H),7.2-7.5(m,12H);MS[M-Br]+:472;mp 199℃。
实施例3
3(R)-[2,2-双(4-氟苯基)-2-羟基乙酰氧基]-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a合成标题化合物。最终步骤的产量为400mg,85%。1H-NMR(pMSO-d6):δ1.5-1.65(m,1H),1.7-1.8(m,1H),1.85-2.0(m,2H),2.05-2.2(m,2H),2.3(m,1H),3.1-3.2(m,1H),3.3-3.5(m,6H),3.95(m,1H),4.05(m,2H),5.25(m,1H),6.9-7.0(m,4H),7.1-7.5(m,10H);MS[M-Br]+:508;mp 253℃。
实施例4
3(R)-[2,2-双(4-氟苯基)-2-羟基乙酰氧基]-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a合成标题化合物。最终步骤的产量为300mg,67%。1H-NMR(DMSO-d6):δ1.5-1.65(m,1H),1.7-1.85(m,1H),1.85-2.1(m,2H),2.3(m,1H),2.9-3.1(m,2H),3.15-3.25(m,1H),3.3-3.6(m,6H),3.95-4.05(m,1H),5.25(m,1H),6.95(s,OH),7.1-7.5(m,13H);MS[M-Br]+:478;mp 182℃。
实施例5
3(R)-(2-羟基-2,2-二-对-甲苯基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a合成标题化合物。最终步骤的产量为500mg,54%。1H-NMR(DMSO-d6):δ1.55-1.8(m,2H),1.85-2.0(m,2H),2.05-1.15(m,2H),2.3(s,7H),3.05-3.15(m,1H),3.25-3.5(m,6H),3.95(m,1H),4.05(t,2H),5.2(m,1H),6.8(s,OH),6.95(m,3H),7.1-7.2(m,4H),7.2-7.35(m,6H);MS[M-Br]+:500;mp 183℃。
实施例6
3(R)-(2-羟基-2,2-二-对-甲苯基乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a合成标题化合物。最终步骤的产量为650mg,74%。1H-NMR(DMSO-d6):δ1.55-1.8(m,2H),1.85-2.05(m,2H),2.25(s,7H),2.9-3.05(m,2H),3.1-3.25(m,1H),3.3-3.55(m,6H),3.95(m,1H),5.25(m,1H),6.8(s,OH),7.1-7.2(m,4H),7.2-7.35(m,9H);MS[M-Br]+:470;mp 144℃。
实施例7
3(R)-(2,2-二苯基丙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法e和a合成标题化合物。最终步骤的产量为250mg,61%。1H-NMR(CDCl3):δ1.47-1.60(m,1H),1.8-2.0(m,1H),2.0(s,3H),2.0-2.15(m,4H),2.39(s,1H),2.6(m,1H),2.92(d,1H),3.6(m,1H),3.7-3.9(m,4H),4.0(m,2H),4.3(m,1H),5.25(m,1H),6.85(m,2H),7.0(m,1H),7.3(m,12H);MS[M-Br]+:470;mp 186℃。
实施例8
3(R)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a合成为非对映体混合物的标题化合物。最终步骤的产量为520mg,62%。1H-NMR(DMSO-d6):δ1.5-1.95(m,4H),2.1(m,2H),2.3(m,1H),3.1(m,1H),3.3-3.5(m,6H),3.9(m,1H),4.05(t,2H),5.2(m,1H),7.0(m,4H),7.15(m,2H),7.35(m,5H),7.5(m,3H);MS[M-Br]+:478;mp 220℃。
实施例9
3(R)-[2(R)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体1合成标题化合物。最终步骤的产量为10mg,23%。1H-NMR(DMSO-d6):δ1.5-1.6(m,1H),1.65-1.75(m,1H),1.8-2.0(m,2H),2.05-2.1(m,2H),2.3(m,1H),3.05-3.2(m,1H),3.25-3.55(m,6H),3.85-3.95(m,1H),4.0(t,2H),5.2(m,1H),6.95(m,3H),7.03(m,1H),7.15(dd,1H),7.2(s,OH),7.3-7.5(m,5H),7.45-7.55(m,3H);MS[M-CF3COO]+:478。
实施例10
3(R)-[2(S)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体2合成标题化合物。最终步骤的产量为3mg,11%。1H-NMR(DMSO-d6):δ1.6-1.75(m,2H),1.8-2.0(m,4H),2.25(m,1H),2.8(t,2H),2.95-3.1(m,1H),3.15-3.5(m,6H),3.8-3.95(m,1H),5.2(m,1H),6.92(m,1H),6.96-7.03(m,2H),7.1(dd,1H),7.18(s,OH),7.3-7.4(m,4H),7.43-7.5(m,2H),7.51(dd,1H);MS[M-CF3COO]+:478。
实施例11
3(R)-[2(R)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-苯基乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体1合成标题化合物。最终步骤的产量为9mg,22%。1H-NMR(DMSO-d6):δ1.45-1.55(m,1H),1.65-1.75(m,1H),1.85-2.05(m,2H),2.3(m,1H),2.9-3.1(m,2H),3.1-3.25(m,1H),3.25-3.55(m,6H),3.9-4.0(m,1H),5.25(m,1H),7.05(m,1H),7.15(m,1H),7.2(m,1H),7.25-7.4(m,8H),7.45(m,2H),7.55(m,1H);MS[M-CF3COO]-:448。
实施例12
3(R)-[2(R)-(2羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(3-苯基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体1合成标题化合物。最终步骤的产量为11mg,26%。1H-NMR(DMSO-d6):δ1.45-1.55(m,1H),1.6-1.75(m,1H),1.8-2.0(m,4H),2.25(m,1H),2.55(t,2H),3.0-3.1(m,1H),3.15-3.55(m,6H),3.8-3.9(m,1H),5.2(m,1H),7.0(m,1H),7.1(m,1H),7.15-7.4(m,9H),7.45(m,2H),7.5(m,1H);MS[M-CF3COO]-:462。
实施例13
3(R)-[2(R)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体1合成标题化合物。最终步骤的产量为10mg,24%。1H-NMR(DMSO-d6):δ1.45-1.55(m,1H),1.65-1.75(m,1H),1.8-2.0(m,2H),2.3(m,1H),3.1-3.6(m,9H),3.9-4.0(m,1H),5.25(m,1H),7.0(m,3H),7.15(dd,1H),7.2(s,OH),7.3-7.4(m,3H),7.45-7.55(m,4H);MS[M-CF3COO]+:454。
实施例14
3(R)-[2(R)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体1合成标题化合物。最终步骤的产量为8mg,19%。1H-MR(DMSO-d6):δ1.45-1.6(m,1H),1.65-1.75(m,1H),1.8-2.05(m,4H),2.25(m,1H),2.8(t,2H),3.0-3.15(m,1H),3.2-3.5(m,6H),3.8-3.95(m,1H),5.2(m,1H),6.92(m,1H),6.96-7.03(m,2H),7.13(dd,1H),7.2(s,OH),7.3-7.4(m,4H),7.45-7.5(m,2H),7.52(dd,1H);MS[M-CF3COO]+:468。
实施例15
3(R)-[2(S)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体2合成标题化合物。最终步骤的产量为7mg,26%。1H-NMR(DMSO-d6):δ1.6-1.75(m,2H),1.8-2.0(m,4H),2.25(m,1H),2.8(t,2H),2.95-3.1(m,1H),3.15-3.5(m,6H),3.8-3.95(m,1H),5.2(m,1H),6.92(m,1H),6.96-7.03(m,2H),7.1(dd,1H),7.18(s,OH),7.3-7.4(m,4H),7.43-7.5(m,2H),7.51(dd,1H);MS[M-CF3COO]+:468。
实施例16
3(R)-[2(2)-(2-羟基-2-苯基-2-噻吩-2-基乙酰氧基)]-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法f和b,从中间体I-4f,非对映体1合成标题化合物。最终步骤的产量为11mg,26%。1H-NMR(DMSO-d6):δ1.5-1.6(m,1H),1.65-1.75(m,1H),1.8-2.0(m,2H),2.25(m,1H),3.15-3.6(m,5H),3.7(m,2H),4.0(m,2H),4.4(m,2H),5.25(m,1H),6.95-7.03(m,4H),7.12(dd,1H),7.2(s,OH),7.3-7.4(m,5H),7.4-7.5(m,3H);MS[M-CF3COO]+:464。
实施例17
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成为非对映体混合物的标题化合物。最终步骤的产量为240mg,77%。1H-NMR(DMSO-d6):δ1.55-2.0(m,4H),2.27(m,1H),3.05-3.55(m,5H),3.88-3.98(m,1H),4.0-4.10(m,2H),5.21(m,1H),6.23-6.31(双峰dd,1H),6.36-6.48(m,2H),6.83-6.90(dd,1H),6.95(d,OH),7.26-7.66(m,11H);MS[M-Br]+:444;mp 99℃。
实施例18
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成为非对映体混合物的标题化合物。最终步骤的产量为210mg,66%。1H-NMR(DMSO-d6):δ1.50-2.05(m,4H),2.27(m,1H),3.20(m,1H),3.37-3.65(m,4H),3.65-3.75(m,2H),4.04(m,1H),4.40(m,2H),5.21(m,1H),6.23-6.32(双峰dd,1H),6.44(m,1H),6.94-7.04(m,4H),7.33-7.50(m,7H),7.64(m,1H);MS[M-Br]+:448;mp 163℃。
实施例19
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体1,合成标题化合物。最终步骤的产量为11mg,23%。1H-NMR(DMSO-d6):δ1.65-1.80(m,2H),1.80-2.10(m,2H),2.27(m,1H),3.15-3.65(m,5H),3.68(m,2H),4.0(m,1H),4.40(t,2H),5.20(m,1H),6.23(d,1H),6.42(m,1H),6.92-7.04(m,4H),7.30-7.38(m,5H),7.44-7.50(m,2H),7.64(m,1H);MS[M-CF3COO]+:448。
实施例20
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
标题化合物已描述在方法-a-中。
实施例21
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,从中间体I-1a,非对映体1,合成标题化合物。最终步骤的产量为1.15g,99%。1H-NMR(DMSO-d6):δ1.60-2.20(m,6H),2.25(m,1H),3.10(m,1H),3.20-3.60(m,6H),3.95(m,1H),4.05(m,2H),5.20(m,1H),6.25(dd,1H),6.45(m,1H),6.95(m,4H),7.30-7.50(m,7H),7.70(m,1H);MS[M-Br]+:462;mp 156℃。
实施例22
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体2,合成标题化合物。最终步骤的产量为10mg,20%。1H-NMR(DMSO-d6):δ1.50-2.20(m,6H),2.25(m,1H),3.10(m,1H),3.20-3.60(m,6H),3.95(m,1H),4.05(m,2H),5.20(m,1H),6.35(dd,1H),6.45(m,1H),6.95(m,4H),7.30-7.50(m,7H),7.70(m,1H);MS[M-CF3COO]+:462。
实施例23
3(R)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成为非对映体混合物的标题化合物。最终步骤的产量为12mg,13%。1H-NMR(DMSO-d6):δ1.5(m,1H),1.7(m,1H),1.9-2.05(m,2H),2.3(m,1H),2.95(m,2H),3.15(m,1H),3.25-3.55(m,6H),3.95(m,1H),5.25(m,1H),6.3(d,1H),6.45(m,1H),6.95(d,1H),7.25-7.45(m,8H),7.5(m,2H),7.7(m,1H);MS[M-CF3COO]+:432。
实施例24
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体1,合成标题化合物。最终步骤的产量为16mg,40%。1H-NMR(DMSO-d6):δ1.65-1.80(m,2H),1.90-2.05(m,2H),2.3(m,1H),2.95(m,2H),3.15(m,1H),3.25-3.55(m,6H),3.95(m,1H),5.25(m,1H),6.26(dd,1H),6.46(m,1H),6.95(s,1H,OH),7.25-7.45(m,8H),7.5(m,2H),7.7(m,1H);MS[M-CF3COO]+:432。
实施例25
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体2,合成标题化合物。最终步骤的产量为14mg,35%。1H-NMR(DMSO-d6):δ1.50-1.80(m,2H),1.90-2.05(m,2H),2.3(m,1H),2.95(m,2H),3.15(m,1H),3.25-3.55(m,6H),3.95(m,1H),5.25(m,1H),6.32(dd,1H),6.46(m,1H),6.95(s,1H,OH),7.25-7.45(m,8H),7.5(m,2H),7.7(m,1H);MS[M-CF3COO]+:432。
实施例26
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-(3-苯基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体1,合成标题化合物。最终步骤的产量为10mg,21%。1H-NMR(DMSO-d6):δ1.60-1.75(m,2H),1.80-2.0(m,4H),2.25(m,1H),2.50-2.60(m,2H),3.0(m,1H),3.10-3.50(m,6H),3.83(m,1H),5.17(m,1H),6.25(d,1H),6.45(m,1H),6.95(s,1H),7.20-7.40(m,8H),7.46-7.48(m,2H),7.66(m,1H);MS[M-CF3COO]+:446。
实施例27
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体1,合成标题化合物。最终步骤的产量为9mg,19%。1H-NMR(DMSO-d6):δ1.65-1.80(m,2H),1.85-2.05(m,2H),2.30(m,1H),3.10-3.40(m,3H),3.40-3.60(m,6H),3.95(m,1H),5.24(m,1H),6.27(d,1H),6.47(m,1H),6.96(s,1H),7.0-7.04(m,2H),7.36-7.48(m,4H),7.49-7.54(m,2H),7.70(m,1H);MS[M-CF3COO]+:438。
实施例28
3(R)-[2(*)-(2-呋喃-2-基-2-羟基-2-苯基乙酰氧基)]-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,从中间体I-1a,非对映体1,合成标题化合物。最终步骤的产量为9mg,19%。1H-NMR(DMSO-d6):δ1.60-1.75(m,2H),1.80-2.05(m,4H),2.26(m,1H),2.81(t,2H),3.02(m,1H),3.10-3.45(m,6H),3.85(m,1H),5.18(m,1H),6.25(d,1H),6.45(m,1H),6.90-7.0(m,3H),7.32-7.42(m,4H),7.45-7.51(m,2H),7.66(m,1H);MS[M-CF3COO]+:452。
实施例29
3(R)-(2-呋喃-2-基-2-羟基-2-噻吩-2-基乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成为非对映体混合物的标题化合物。最终步骤的产量为18mg,20%。1H-NMR(DMSO-d6):δ1.65-2.05(m,4H),2.3(m,1H),3.0(m,2H),3.15-3.6(m,7H),3.95(m,1H),5.25(m,1H),6.35(dd,1H),6.45(m,1H),7.05(m,1H),7.2(dd,1H),7.25-7.5(m,6H),7.55(m,1H),7.65(m,1H);MS[M-CF3COO]+:438。
实施例30
3(R)-(2-呋喃-2-基-2-羟基-2-噻吩-2-基乙酰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成为非对映体混合物的标题化合物。最终步骤的产量为22mg,23%。1H-NMR(DMSO-d6):δ2.65-2.05(m,4H),2.3(m,1H),3.15-3.65(m,7H),4.05(m,1H),4.4(m,2H),5.15(m,1H),6.35(dd,1H),6.45(m,1H),6.95-7.05(m,4H),7.15(d,1H),7.3-7.4(m,3H),7.5(dd,1H),7.65(d,1H);MS[M-CF3COO]+:454。
实施例31
3(R)-(2-呋喃-2-基-2-羟基-2-噻吩-2-基乙酰氧基)-1-(4-氧代-4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成为非对映体混合物的标题化合物。最终步骤的产量为15.4mg,15%。1H-NMR(DMSO-d6):δ1.65-2.1(m,6H),7.05-7.55(m,9H),3.95(m,1H),5.1(m,1H),6.35(dd,1H),6.5(m,1H),7.05(m,1H),7.15(m,1H),7.3(d,1H),7.55(m,3H),7.7(dd,2H),8.0(d,2H);MS[M-CF3COO]+:480。
实施例32
1-(3-苯氧基丙基)-3(R)-(2-呋喃-2-基-2-羟基-2-噻吩-2-基-乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成为非对映体混合物的标题化合物。最终步骤的产量为100mg,41%。1H-NMR(DMSO-d6):δ1.65-2.05(m,4H),2.1-2.0(m,2H),2.3(m,1H),3.15(m,1H),3.25-3.6(6H),3.9-4.1(m,3H),5.1(m,1H),6.35(d,1H),6.45(s,1H),6.95(m,3H),7.05(m,1H),7.2(d,1H),7.3(m,3H),7.55(d,1H),7.7(s,1H);MS[M-Br]+:520;mp 173℃。
实施例33
1-(3-苯氧基丙基)-3(R)-(2,2-二呋喃-2-基-2-羟基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法f和a,合成标题化合物。最终步骤的产量为200mg,60%。1H-NMR(DMSO-d6):δ1.6-2.20(m,6H),2.3(m,1H),2.95-3.65(m,7H),3.80-4.10(m,3H),5.2(m,1H),6.3-6.6(m,4H),6.8-7.0(m,3H),7.1(s,OH),7.3(m,2H),7.7(m,2H);MS[M-Br]+:452。
实施例34
3(R)-(2,2-二噻吩-2-基乙酰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为240mg,60%。1H-NMR(DMSO-d6):δ1.85-2.10(m,4H),2.30(s,1H),3.40(m,1H),3.44-3.80(m,6H),4.10(m,1H),4.45(m,2H),5.20(m,1H),5.90(s,1H),6.95-7.05(m,5H),7.05-7.15(m,2H),7.30-7.40(m,2H),7.45(m,2H);MS[M-Br]+:454;mp 98℃。
实施例35
3(R)-(2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为280mg,83%。1H-NMR(DMSO-d6):δ1.80-2.06(m,4H),2.06-2.20(m,2H),2.20-2.30(m,1H),3.20-3.65(m,7H),3.90-4.10(m,3H),5.20(m,1H),5.90(s,1H),6.95-7.05(m,5H),7.05-7.20(m,2H),7.30-7.35(m,2H),7.50(m,2H);MS[M-Br]+:468;mp 148℃。
实施例36
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为180mg,59%。1H-NMR(DMSO-d6):δ1.65-2.0(4H,m),2.35(m,]H),3.0(m,2H),3.2-3.6(m,7H),3.95(m,1H),5.25(m,1H),7.0(m,2H),7.2(m,2H),7.35(m,5H),7.55(m,3H);MS[M-Br]+:454;mp 216℃。
实施例37
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为450mg,58%。1H-NMR(CDCl3):δ1.8-2.1(m,6H),2.4(m,1H),2.6(m,2H),3.4-3.8(m,7H),4.2(m,1H),5.25(m,1H),6.1(bs,OH),6.9(m,2H),7.1-7.3(m,9H);MS[M-Br]+:468;mp 64℃。
实施例38
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为260mg,34%。1H-NMR(CDCl3):δ1.8-2.05(m,4H),2.4(m,1H),3.55-3.95(m,5H),4.15-4.5(m,3H),5.25(m,1H),5.9(s,OH),6.15(m,1H),6.85(t,1H),6.9-7.05(m,3H),7.15(m,1H),7.2-7.45(m,7H);MS[M-Br]+:466;mp 124℃。
实施例39
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为320mg,40%。1H-NMR(CDCl3):δ1.6-2.0(m,8H),2.4(m,1H),2.6(m,2H),3.4-3.8(m,7H),4.2(m,1H),5.25(m,1H),6.05(bs,OH),6.95(m,2H),7.1-7.3(m,9H);MS[M-Br]+:482;mp 64℃。
实施例40
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(4-氧代-4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.7-2.0(m,6H),2.15(m,1H),3.1(t,2H),3.15-3.55(m,7H),3.95(m,1H),5.25(m,1H),7.0(d,2H),7.15(d,2H),7.55(m,5H),7.65(t,1H),8.0(d,2H);MS[M-CF3COO]+:496。
实施例41
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯基氨基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,14%。1H-NMR(DMSO-d6):δ1.7-2.0(m,5H),2.3(m,1H),3.0-3.5(m,9H),3.9(m,1H),5.25(m,1H),5.65(t,1H),6.55(m,3H),7.0(d,2H),7.1(t,2H),7.15(m,2H),7.5(m,3H);MS[M-CF3COO]+:483。
实施例42
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(甲基苯基氨基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为20mg,19%。1H-NMR(DMSO-d6):δ1.65-2.0(m,6H),2.9(s,3H),3.1(m,1H),3.2-3.45(m,8H),3.95(m,1H),5.2(m,1H),6.65(t,1H),6.75(d,2H),7.0(m,2H),7.2(m,4H),7.5(m,3H);MS[M-CF3COO]+:497。
实施例43
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯硫基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为800mg,83%。1H-NMR(DMSO-d6):δ1.6-1.9(m,6H),2.3(m,1H),2.95(t,2H),3.05(m,1H),3.2-3.5(m,6H),3.9(m,1H),5.2(m,1H),7.0(m,2H),7.15(m,2H),7.2(m,1H),7.35(m,4H),7.5(m,2H);MS[M-Br]+:500。
实施例44
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为490mg,90%。1H-NMR(DMSO-d6):δ1.7(m,2H),1.95(m,2H),2.1(m,2H),2.3(m,1H),3.2(m,1H),3.45(m,6H),4.0(m,3H),5.15(m,1H),6.9(m,3H),7.0(m,2H),7.2(m,2H),7.3(t,2H),7.5(m,3H);MS[M-Br]+:484;mp 227℃。
实施例45
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-邻-甲苯基氧基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,18%。1H-NMR(DMSO-d6):δ1.7-2.0(m,4H),2.1-2.2(m,5H),2.3(m,1H),3.15-3.5(m,7H),3.9-4.05(m,3H),5.05(m,1H),6.85(t,1H),6.9(d,1H),7.0(m,2H),7.15(m,4H),7.5(m,3H);MS[M-CFCCOO]+:498。
实施例46
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(2,4,6-三甲基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为22mg,20%。1H-NMR(DMSO-d6):δ1.7(m,2H),1.95(m,2H),2.1(m,2H),2.2(s,9H),2.35(m,1H),3.2-3.5(m,7H),3.7(t,2H),3.95(m,1H),5.25(m,1H),6.8(s,2H)7.0(m,2H),7.2(m,2H),7.5(m,3H);MS[M-CF3COO]+:526。
实施例47
1-[3-(2-叔丁基-6-甲基苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,16%。1H-NMRR(DMSO-d6):δ1.3(s,9H),2.7(m,2H),2.9(m,2H),2.1(m,2H),2.2(s,3H),2.3(m,1H),3.2-3.5(m,7H),3.8(t,2H),3.95(m,1H),5.2(m,1H),6.9-7.15(m,7H),7.5(m,3H);MS[M-CF3COO]+:554。
实施例48
1-[3-(联苯基-4-基氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为22mg,19%。1H-NMR(DMSO-d6):δ1.7(m,2H),1.9(m,2H),2.15(m,2H),2.3(m,1H),3.2-3.5(m,7H),3.95(m,1H),4.1(t,2H),5.25(m,1H),7.0(m,4H),7.2(m,2H),7.3(t,1H),7.45(t,2H),7.5(m,3H),7.6(m,4H);MS[M-CF3COO]+:560。
实施例49
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(5,6,7,8-四氢萘-2-基氧基)-丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为23mg,21%。1H-NMR(DMSO-d6):δ1.7(m,6H),1.9-2.1(m,4H),2.3(m,1H),2.65(m,4H),3.15-3.5(m,7H),3.95(m,2H),5.25(m,1H),6.65(m,2H),6.95(d,1H),7.0(m,2H),7.2(m,2H),7.5(m,3H);MS[M-CF3COO]+:538。
实施例50
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(萘-2-基氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为17mg,15%。1H-NMR(DMSO-d6):δ1.7-2.0(m,4H),2.1(m,1H),2.35(m,1H),3.15-3.35(m,7H),3.95(m,1H),4.17(t,2H),5.25(m,1H),7.0(m,2H),7.15(m,3H),7.35(m,2H),7.5(m,4H),7.85(m,3H);MS[M-CF3COO]+:534。
实施例51
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(萘-1-基氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
标题化合物已经被描述于方法-b-中。
实施例52
1-[3-(2-氯代苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为20mg,18%。1H-NMR(DMSO-d6):δ1.65-2.0(m,6H),2.35(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.95(m,1H),4.15(t,2H),5.25(m,2H),7.0(m,3H),7.2(m,3H),7.35(t,1H),7.45(d,1H),7.55(m,3H);MS[M-CF3COO]+:519。
实施例53
1-[3-(4-氟苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;氯化物
按照方法c和a,合成标题化合物。最终步骤的产量为180mg,59%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.25(m,1H),3.2(m,1H),3.25-3.55(m,6H),3.95(m,2H),4.0(t,2H),5.25(m,1H),7.0(m,4H),7.15(m,4H),7.55(m,3H);MS[M-Cl]+:502;mp 160℃。
实施例54
1-[3-(2,4-二氟苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,13%。1H-NMR(DMSO-d6):δ1.65-2.0(m,4H),2.15(m,2H),2.35(m,1H),3.2(m,1H),3.25-3.35(m,6H),3.95(m,1H),4.1(t,2H),5.15(m,1H),7.05(m,3H),7.2(d,2H),7.25-7.35(m,2H),7.55(m,3H);MS[M-CF3COO]+:520。
实施例55
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(3-三氟甲基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,17%。1H-NMR(DMSO-d6):δ1.65-2.1(m,6H),2.35(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.95(m,1H),4.15(t,2H),5.25(m,1H),7.0(m,2H),7.2(m,2H),7.25-7.35(m,3H),7.5-7.6(m,4H);MS[M-CF3COO]+:552。
实施例56
1-[3-(3-氰基苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,17%。1H-NMR(DMSO-d6):δ1.65-2.1(m,6H),2.35(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.95(m,1H),4.15(t,2H),5.25(m,1H),7.0(m,2H),7.18(m,2H),7.3(d,1H),7.45(m,2H),7.55(m,4H);MS[M-CF3COO]+:509。
实施例57
1-[3-(4-氰基苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为180mg,53%。1H-NMR(DMSO-d6):δ1.65-2.2(m,6H),2.3(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.95(m,1H),4.15(t,2H),5.25(m,1H),7.0(m,2H),7.1(d,2H),7.15(m,2H),7.5(m,2H),7.8(d,2H);MS[M-Br]+:509;mp 158℃。
实施例58
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(3-甲氧基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,18%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.15(m,1H),3.2(m,1H),3.3-3.5(m,6H),3.75(s,3H),3.95(m,1H),4.0(t,2H),5.25(m,1H),6.55(m,3H),7.0(m,2H),7.2(m,3H),7.55(m,3H);MS[M-CF3COO]+:514。
实施例59
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(4-甲氧基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,13%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.35(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.7(s,3H),3.9-4.0(m,3H),5.25(m,1H),6.9(s,4H),7.0(m,2H),7.15(m,2H),7.5(m,3H);MS[M-CF3COO]+:514。
实施例60
1-[3-(苯并[1,3]二氧杂环戊-5-基氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,17%。1H-MR(DMSO-d6):δ1.65-2.15(m,7H),2.3(m,1H),3.15(m,1H),3.25-3.5(m,6H),3.9-4.0(m,3H),5.25(m,1H),5.95(s,2H),6.4(d,1H),6.65(s,1H),6.85(d,1H),7.0(m,2H),7.2(m,2H),7.5(m,3H);MS[M-CF3COO]+:528。
实施例61
1-[3-(2-氨基甲酰基苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,16%。1H-NMR(DMSO-d6):δ1.65-2.0(m,4H),2.2(m,2H),2.3(m,1H),3.15(m,1H),3.25-3.55(m,6H),3.95(m,1H),4.15(t,2H),5.25(m,1H),7.0-7.2(m,6H),7.4-7.6(m,6H),7.7(d,1H);MS[M-CF3COO]+:527。
实施例62
1-[3-(3-二甲基氨基苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,17%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.3(m,1H),2.85(s,6H),3.1-3.5(m,7H),3.85-4.0(m,3H),5.25(m,1H),6.2(m,1H),6.25(d,1H),6.35(d,1H),7.0(m,2H),7.1(t,1H),7.2(m,2H),7.5(m,3H);MS[M-CF3COO]+:527。
实施例63
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(4-硝基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为22mg,20%。1H-NMR(DMSO-d6):δ1.65-2.0(m,4H),2.2(m,2H),2.3(m,1H),3.2(m,1H),3.3-3.5(m,6H),3.95(m,1H),4.2(t,2H),5.25(m,1H),7.0(m,2H),7.15(m,4H),7.5(m,3H),8.15(d,2H);MS[M-CF3COO]+:529。
实施例64
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(3-硝基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,16%。1H-NMR(DMSO-d6):δ1.65-2.2(m,6H),2.3(m,1H),3.15-3.55(m,7H),3.95(m,1H),4.2(t,2H),5.25(m,1H),7.0(m,2H),7.2(m,2H),7.45(dd,1H),7.55(m,3H),7.6(t,1H),7.75(s,1H),7.85(d,1H);MS[M-CF3COO]+:529。
实施例65
1-[3-(4-乙酰基氨基苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,17%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.0(s,3H),2.3(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.9-4.0(m,3H),5.25(m,1H),6.85(d,2H),7.0(m,2H),7.2(m,2H),7.5(m,5H),9.8(s,1H);MS[M-CF3COO]+:541。
实施例66
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(3-甲氧基羰基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,16%。1H-NMR(DMSO-d6):δ1.65-2.2(m,6H),2.3(m,1H),3.2(m,1H),3.3-3.5(m,6H),3.85(s,3H),3.95(m,1H),4.1(t,2H),5.25(m,1H),7.0(m,2H),7.15(m,2H),7.25(dd,1H),7.45-7.6(m,6H);MS[M-CF3COO]+:542。
实施例67
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-{3-[4-(3-羟基丙基)苯氧基]丙基}-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,13%。1H-NMR(DMSO-d6):δ1.6-2.15(m,8H),2.3(m,1H),2.55(t,2H),3.2(m,1H),3.25-3.55(m,9H),3.85-4.0(m,3H),4.45(t,OH),5.25(m,1H),7.85(d,2H),7.0(m,2H),7.1(d,2H),7.15(m,2H),7.5(m,2H);MS[M-CF3COO]+:542。
实施例68
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(2-羟基甲基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.7-2.2(m,6H),2.35(m,1H),3.1-3.5(m,7H),3.9-4.05(m,3H),4.5(m,2H),5.0(t,OH),5.15(m,1H),6.9-7.05(m,4H),7.2(m,2H),7.4(d,1H),7.5(m,3H);MS[M-CF3COO]+:514。
实施例69
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(3-羟基甲基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.7-2.2(m,6H),2.35(m,1H),3.15-3.5(m,7H),3.9(m,1H),4.05(t,2H),4.45(d,2H),5.25(m,2H),6.8(d,1H),6.9(m,2H),7.2(m,2H),7.25(t,1H),7.5(m,3H);MS[M-CF3COO]+:514。
实施例70
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(4-羟基甲基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为17mg,16%。1H-NMR(DMSO-d6):δ1.65-2.2(m,6H),2.3(m,1H),3.15-3.55(m,7H),3.9-4.05(m,3H),4.4(d,2H),5.1(t,OH),5.25(t,1H),6.9(d,2H),7.0(m,2H),7.2(m,2H),7.25(d,2H),7.5(m,3H);MS[M-CF3COO]+:514。
实施例71
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(2-羟基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为24mg,19%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.35(m,1H),3.2(m,1H),3.25-3.55(m,6H),3.95(m,1H),4.0(t,2H),5.25(m,1H),6.7-6.85(m,3H),6.95(d,1H),7.0(m,2H),7.2(m,2H),7.5(m,3H),8.85(s,OH);MS[M-CF3COO]+:500。
实施例72
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(4-羟基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.65-2.1(m,6H),2.3(m,1H),3.2(m,1H),3.25-3.5(m,6H),3.95(m,3H),5.25(m,1H),6.7(d,2H),6.75(d,2H),7.0(m,2H),7.2(m,2H),7.5(t,3H),9.0(s,OH);MS[M-CF3COO]+:500。
实施例73
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[3-(3-羟基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.65-2.15(m,6H),2.3(m,1H),3.2(m,1H),3.3-3.55(m,6H),3.9-4.0(m,3H),5.25(m,1H),6.9-6.0(m,3H),7.0-7.1(m,3H),7.2(m,2H),7.5(m,3H),9.45(s,OH);MS[M-CF3COO]+:500。
实施例74
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-吡咯-1-基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为21mg,22%。1H-NMR(DMSO-d6):δ1.65-1.8(m,2H),1.8-2.0(m,2H),2.0-2.15(m,2H),2.3(m,1H),3.05-3.2(m,3H),3.2-3.5(m,4H),3.8-3.95(m,3H),5.2(m,1H),6.05(t,2H),6.75(t,2H),7.0(t,2H),7.15(d,2H),7.55(m,3H);MS[M-CF3COO]+:457。
实施例75
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(4-氧代-4-噻吩-2-基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,17%。1H-NMR(DMSO-d6):δ1.7-1.85(m,2H),1.9-2.1(m,4H),2.3(m,1H),3.1(t,2H),3.15-3.55(m,7H),3.95(m,1H),5.25(m,1H),7.0(t,2H),7.4(d,2H),7.25(t,1H),7.55(m,3H),7.95(d,1H),8.05(d,1H);MS[M-CF3COO]+:502。
实施例76
3(R)-(2-羟基-2,2-二噻吩-2-甚乙酰氧基)-1-[3-(1-甲基-[1H]-咪唑-2-基硫烷基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为26mg,25%。1H-NMR(DMSO-d6):δ1.7(m,2H),1.85-2.05(m,4H),2.3(m,1H),3.25-3.5(m,7H),3.6(s,3H),3.9(m,1H),4.2(t,2H),5.2(m,1H),7.0(m,3H),7.15(m,2H),7.3(m,1H),7.5(m,3H);MS[M-CF3COO]+:504。
实施例77
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为430mg,54%。1H-NMR(DMSO-d6):δ1.6-1.8(m,2H),2.3(m,1H),3.15-3.3(m,4H),3.35-3.55(m,5H),3.95(m,1H),5.25(m,1H),7.0(m,4H),7.15(m,2H),7.4-7.5(m,4H);MS[M-Br]+:460;mp 206℃。
实施例78
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为600mg,77%。1H-NMR(DMSO-d6):δ1.6-1.8(m,2H),1.85-2.1(m,4H),2.3(m,1H),2.8(t,2H),3.1-3.5(m,7H),3.9(m,1H),5.2(m,1H),6.9-7.05(m,4H),7.15(m,2H),7.4(d,1H),7.5(m,3H);MS[M-Br]+:474;mp 138℃。
实施例79
1-[3-(苯并噻唑-2-基氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为23mg,21%。1H-NMR(DMSO-d6):δ1.65-2.1(m,6H),2.3(m,1H),3.15(m,1H),3.25-3.5(m,6H),3.85(m,1H),4.0(t,2H),5.2(m,1H),7.0(t,2H),7.15(m,2H),7.25(m,1H),7.45(m,5H),7.7(d,1H);MS[M-CF3COO]+:541。
实施例80
1-(3-苄氧基丙基)-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.65(m,2H),1.9(m,4H),2.3(m,1H),3.1-3.4(m,7H),3.5(t,2H),3.9(m,1H),3.9(s,2H),5.2(m,1H),7.0(m,2H),7.15(m,2H),7.35(m,5H),7.5(m,3H);MS[M-CF3COO]+:498。
实施例81
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-[6-(4-苯基丁氧基)己基]-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为560mg,60%。1H-NMR(CDCl3):δ1.2-1.75(m,16H),1.8-2.1(m,4H),2.4(m,1H),2.6(t,2H),3.3-3.75(m,11H),4.2(m,1H),5.3(m,1H),6.0(bs,OH),6.95(m,2H),7.15-7.3(m,9H);MS[M-Br]+:582。
实施例82
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(4-苯氧基丁基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为240mg,30%。1H-NMR(DMSO-d6/CDCl3):δ1.8-1.95(m,6H),2.1(m,2H),2.45(m,1H),3.18(m,1H),3.5-3.8(m,6H),4.0(t,2H),4.15(m,1H),5.15(m,1H),6.7(s,OH),6.9(m,5H),7.15(d,1H),7.25(m,5H);MS[M-Br]+:498;mp 161℃。
实施例83
3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为380mg,50%。1H-NMR(DMSO-d6):δ1.85(m,2H),2.05(m,2H),2.4(m,1H),3.6-4.1(m,7H),4.35(m,3H),5.25(m,1H),6.0(bs,OH),6.9(m,4H),7.0(t,1H),7.1(dd,2H),7.2(dd,2H),7.3(t,2H);MS[M-Br]-:470;mp 48℃。
实施例84
1-(2-苄氧基乙基)-3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为17mg,17%。1H-NMR(DMSO-d6):δ1.65-2.0(m,4H),2.3(m,1H),3.2-3.55(m,7H),3.85(m,2H),4.5(s,2H),5.25(m,1H),7.0(t,2H),7.15(t,2H),7.3-7.4(m,4H),7.5(m,3H);MS[M-CF3COO]+:484。
实施例85
3(S)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为600mg,54%。1H-NMR(DMSO-d6/CDCl3):δ1.85-2.3(m,6H),2.5(m,1H),3.3(m,1H),3.4(d,1H),3.5-3.7(m,5H),4.05(t,2H),4.2(m,1H),5.25(m,1H),6.85(d,2H),7.0(m,3H),7.15(m,2H),7.2(d,1H),7.3(m,4H);MS[M-Br]+:484;mp 230℃。
实施例86
4-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法f和a,合成标题化合物。最终步骤的产量为290mg,60%。1H-NMR(DMSO-d6):δ2.15(m,2H),2.35(m,6H),3.35(m,2H),3.65(m,6H),4.05(t,2H),6.9-7.05(m,5H),7.1(m,2H),7.3(m,3H),7.55(m,2H);MS[M-Br]+:484;mp 168℃。
实施例87
4-(2-羟基-2,2-二噻吩-2-基-乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法f和a,合成标题化合物。最终步骤的产量为260mg,57%。1H-NMR(DMSO-d6):δ2.35(m,6H),3.0(m,2H),3.4(m,2H),3.75(m,6H),7.0(m,2H),7.3-7.5(m,6H),7.55(m,2H);MS[M-Br]+:454;mp 195℃。
实施例88
1-(3-苯氧基丙基)-3(R)-(2,2-二噻吩-2-基丙酰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为390mg,92%。1H-NMR(DMSO-d6):δ1.65-2.20(m,6H),2.10(s,3H),2.30(bs,1H),3.10(m,1H),3.30-3.60(m,6H),3.95-4.10(m,3H),5.20(m,1H),6.90-7.05(m,5H),7.05-7.10(m,2H),7.25-7.35(m,2H),7.50(m,2H);MS[M-Br]+:482;mp 170℃。
实施例89
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为300mg,76%。1H-NMR(DMSO-d6):δ1.6(m,1H),1.75(m,1H),1.8-2.0(m,2H),2.0-2.2(m,2H),2.3(m,1H),3.15(m,1H),3.3-3.6(m,6H),3.9(m,1H),4.05(t,2H),5.2(m,1H),6.75(s,OH),6.95(m,3H),7.15(m,2H),7.3(t,2H),7.4-7.5(m,4H);MS[M-Br]+:484;mp 219℃。
实施例90
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为300mg,77%。1H-NMR(DMSO-d6):δ1.5-1.6(m,1H),1.6-1.75(m,1H),1.8-2.1(m,4H),2.25(m,1H),2.8(t,2H),3.05-3.5(m,7H),3.8-3.95(m,1H),5.15(m,1H),6.75(s,OH),6.9-7.0(m,2H),7.1(m,2H),7.35-7.55(m,5H);MS[M-Br]+:474;mp 192℃。
实施例91
3(R)-(2-羟基-2,2-二噻吩-3-基-乙酰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为63mg,48%。1H-NMR(DMSO-d6):δ1.5-1.7(m,1H),1.7-1.85(m,1H),1.9-2.1(m,2H),2.3(m,1H),2.9-3.1(m,2H),3.15-3.6(m,7H),3.9-4.0(m,1H),5.2(m,1H),6.8(s,OH),7.1(m,2H),7.25-7.35(m,5H),7.4(m,2H),7.5(m,2H);MS[M-CF3COO]+:454。
实施例92
3(R)-(2-羟基-2,2-二噻吩-3-基-乙酰氧基)-1-(3-苯基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为75mg,55%。1H-NMR(DMSO-d6):δ1.5-2.0(m,6H),2.25(m,1H),2.5-2.6(m,2H),3.05-3.6(m,8H),3.8-3.9(m,1H),5.15(m,1H),6.75(s,OH),7.1(d,2H),7.2-7.35(m,5H),7.4(m,2H),7.5(m,2H);MS[M-CF3COO]+:468。
实施例93
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为68mg,48%。1H-NMR(DMSO-d6):δ1.5-1.8(m,6H),1.8-2.0(m,2H),2.25(m,1H),2.6(m,2H),3.05(m,1H),3.15-3.45(m,6H),3.85(m,1H),5.15(m,1H),6.75(s,OH),7.1(d,2H),7.2(m,2H),7.3(m,3H),7.4(m,2H),7.5(m,2H);MS[M-CF3COO]-:482。
实施例94
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为65mg,49%。1H-NMR(DMSO-d6):δ1.5-1.65(m,1H),1.65-1.78(m,1H),1.85-2.05(m,2H),2.3(m,1H),3.1-3.6(m,9H),3.95(m,1H),5.2(m,1H),6.75(s,OH),7.0(m,2H),7.15(m,2H),7.45(m,3H),7.5(m,2H);MS[M-CF3COO]+:460。
实施例95
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(4-苯氧基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为63mg,43%。1H-NMR(DMSO-d6):δ1.5-2.0(m,8H),2.3(m,1H),3.1(m,1H),3.2-3.5(m,6H),3.85(m,1H),4.0(m,2H),5.2(m,1H),6.75(s,OH),6.95(m,3H),7.1(d,2H),7.2(m,2H),7.3(t,2H),7.45(m,2H),7.5(m,2H);MS[M-CF3COO]+:498。
实施例96
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为72mg,52%。1H-NMR(DMSO-d6):δ1.55-1.65(m,1H),1.7-1.8(m,1H),1.85-2.05(m,2H),2.3(m,1H),3.2-3.6(m,5H),3.7(m,2H),4.05(m,1H),4.4(m,2H),5.2(m,1H),6.75(s,OH),6.95-7.05(m,3H),7.1(d,2H),7.3-7.5(m,6H);MS[M-CF3COO]+:470。
实施例97
1-[3-(4-氟苯氧基)丙基]-3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为79mg,54%。1H-NMR(DMSO-d6):δ1.55-1.65(m,1H),1.7-1.8(m,1H),1.85-2.0(m,2H),2.05-2.2(m,2H),2.3(m,1H),3.1-3.2(m,1H),3.25-3.55(m,6H),3.85-3.95(m,1H),4.0(t,2H),5.2(m,1H),6.75(s,OH),6.95(m,2H),7.15(m,4H),7.4(m,2H),7.5(m,2H);MS[M-CF3COO]+:502。
实施例98
3(R)-(2-羟基-2,2-二噻吩-3-基乙酰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为24mg,17%。1H-NMR(DMSO-d6):δ1.8-2.05(m,4H),2.3(m,1H),3.15(m,1H),3.3-3.5(m,4H),3.9(m,1H),4.05(m,2H),5.25(m,1H),6.35(m,1H),6.75(s,OH),6.85(t,1H),7.1(m,2H),7.3-7.5(m,5H),7.55(m,4H);MS[M-CF3COO]+:502。
实施例99
1-(3-苯基烯丙基)-3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为400mg,93%。1H-NMR(DMSO-d6):δ1.35-1.50(m,1H),1.60-1.75(m,1H),1.75-1.95(m,2H),2.10(m,1H),2.85(m,1H),3.10(d,1H),3.20-3.50(m,3H),3.85(m,1H),4.0(dd,2H),5.05(m,1H),6.40(dd,1H),6.80-6.90(d,1H),6.85(s,OH),7.20-7.50(m,7H),7.60(m,4H),7.80(m,2H);MS[M-Br]+:452;mp 146℃。
实施例100
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-(3-苯氧基-丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为690mg,83%。1H-NMR(DMSO-d6):δ1.47(m,1H),1.68(m,1H),1.87(m,2H),2.1(m,3H),2.89(m,1H),3.15(d,1H),3.4(m,5H),3.9(m,1H),4.0(m,2H),5.04(m,1H),6.85(s,OH),6.97(m,3H),7.35(m,4H),7.45(m,2H),7.65(m,2H),7.85(m,2H);MS[M-Br]+:470;mp 108℃。
实施例101
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为170mg,74%。1H-NMR(DMSO-d6):δ1.45(m,1H),1.65(m,1H),1.85(m,2H),2.1(m,1H),2.9(m,3H),3.15(m,1H),3.3-3.5(m,5H),3.85(m,1H),5.05(m,1H),6.85(s,OH),7.2-7.4(m,7H),7.45(t,2H),7.55(d,1H),7.65(d,1H),7.85(d,2H);MS[M-Br]+:440;mp 118℃。
实施例102
3(R)-(9-羟基-9[H]-芴-9-羰氧.基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为460mg,96%。1H-MR(DMSO-d6):δ1.42(m,1H),1.66(m,1H),1.80-1.88(m,2H),2.08(m,1H),2.93(m,1H),3.25-3.60(m,4H),3.65(m,2H),3.95(m,1H),4.35(m,2H),5.02(m,1H),6.85(s,1H,OH),6.97(d,2H),7.04(t,1H),7.20-7.45(m,6H),7.55-7.60(t,2H),7.80(d,2H);MS[M-Br]+:456;mp 140℃。
实施例103
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-(4-氧代-4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为15mg,15%。1H-NMR(DMSO-d6):δ1.45(m,1H),1.65(m,1H),1.7-2.0(m,4H),2.1(m,1H),2.75(m,1H),3.0-3.2(m,4H),3.25-3.4(m,4H),3.85(m,1H),5.05(m,1H),6.85(s,OH),7.35(t,2H),7.45(t,2H),7.55-7.7(m,5H),7.85(d,2H),8.0(d,2H);MS[M-CF3COO]+:482。
实施例104
1-[3-(4-氟苯氧基)丙基]-3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;氯化物
按照方法c和a,合成标题化合物。最终步骤的产量为440mg,94%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,2H),1.7-1.95(m,2H),2.0-2.1(m,3H),2.8(m,1H),3.1(d,1H),3.2-3.4(m,5H),3.8(m,1H),4.0(t,2H),5.0(m,1H),6.85(s,OH),6.95(m,2H),7.15(t,2H),7.35(t,2H),7.45(t,2H),7.55(d,1H),7.65(d,1H),7.85(d,2H);MS[M-Br]+:488;mp 142℃。
实施例105
1-[3-(2,4-二氟苯氧基)丙基]-3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,13%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.6-1.9(m,3H),2.1(m,3H),2.8(m,1H),3.1(d,1H),3.2-3.4(m,5H),3.85(m,1H),4.05(t,2H),5.0(m,1H),6.85(s,OH),7.05(t,1H),7.15-7.4(m,4H),7.45(t,2H),7.55(d,1H),7.65(d,1H),7.85(d,2H);MS[M-CF3COO]+:506。
实施例106
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-(3-苯基氨基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,15%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.6(m,1H),1.8(m,4H),2.05(m,1H),2.7(m,1H),3.0(m,3H),3.2-3.4(m,6H),3.8(m,1H),5.0(m,1H),5.6(t,NH),6.55(m,3H),6.85(s,OH),7.1(t,2H),7.35(dd,2H),7.45(dd,2H),7.55(dd,2H),7.8(d,2H);MS[M-CF3COO]+:469。
实施例107
3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-[3-(4-羟基苯氧基)丙基]-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为15mg,15%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.6(m,1H),1.7-1.9(m,2H),1.95-2.05(m,2H),2.1(m,1H),2.8(m,1H),3.1(d,1H),3.25-3.4(m,5H),3.8-3.9(m,3H),5.0(m,1H),6.7(d,2H),6.75(d,2H),6.85(s,OH),7.35(t,2H),7.45(t,2H),7.55(d,1H),7.65(d,1H),7.85(d,2H),9.0(s,OH);MS[M-CF3COO]+:486。
实施例108
1-(2-苄氧基乙基)-3(R)-(9-羟基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为470mg,96%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.7-1.9(m,2H),2.1(m,1H),2.9(m,1H),3.15-3.5(m,6H),3.75(m,2H),3.85(m,1H),4.5(s,2H),5.0(m,1H),6.85(s,OH),7.3-7.5(m,9H),7.55(m,2H),7.8(d,2H);MS[M-Br]+:470;mp 86℃。
实施例109
3(R)-(9-羟基-9H-芴-9-羰氧基)-1-(3-噻吩基-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为180mg,70%。1H-NMR(DMSO-d6):δ1.37(m,1H),1.62(m,1H),1.75-1.95(m,4H),2.06(m,1H),2.72(m,1H),2.80(m,2H),3.02-3.06(m,1H),3.15-3.20(m,2H),3.25-3.40(m,3H),3.80(m,1H),5.0(m,1H),6.85(s,1H,OH),6.95-7.0(m,2H),7.25-7.50(m,5H),7.55-7.65(m,2H),7.85(d,2H);MS[M-Br]+:460;mp 140℃。
实施例110
3(R)-(9-羟基-9H-芴-9-羰氧基)-1-(3-苯基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为80mg,40%。1H-NMR(DMSO-d6):δ1.35(m,1H),1.6(m,1H),1.7-1.90(m,2H),2.05(m,1H),2.5(m,2H),2.7(m,1H),3.0(m,1H),3.15(m,2H),3.2-3.4(m,3H),3.75(m,1H),5.0(m,1H),6.85(s,OH),7.20-7.50(m,9H),7.55(dd,2H),7.85(d,2H);MS[M-CF3COO]+:454。
实施例111
3(R)-(9-羟基-9H-芴-9-羰氧基)-1-(4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为74mg,35%。1H-NMR(DMSO-d6):δ1.35(m,1H),1.45-1.65(m,5H),1.7-1.90(m,2H),2.05(m,1H),2.55-2.75(m,3H),3.0(m,1H),3.15-3.45(m,5H),3.75(m,1H),5.0(m,1H),6.85(s,OH),7.20(m,3H),7.25-7.35(m,4H),7.45-7.5(m,2H),7.55-7.6(dd,2H),7.85(d,2H);MS[M-CF3COO]+:468。
实施例112
3(R)-(9-羟基-9H-芴-9-羰氧基)-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为79mg,39%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.8-1.95(m,2H),2.1(m,1H),2.9(m,1H),3.1-3.25(m,4H),3.15-3.45(m,5H),3.85(m,1H),5.05(m,1H),6.85(s,OH),7.0(m,2H),7.35(t,2H),7.45-7.5(m,3H),7.55(d,1H),7.65(d,1H),7.85(d,2H);MS[M-CF3COO]+:446。
实施例113
3(R)-(9-羟基-9H-芴-9-羰氧基)-1-(4-苯氧基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为72mg,33%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.55-1.9(m,7H),2.05(m,1H),2.7(m,1H),3.0(m,1H),3.15-3.5(m,7H),3.8(m,1H),4.0(m,2H),5.05(m,1H),6.85(s,OH),6.95(m,3H),7.25-7.35(m,4H),7.4-7.45(m,2H),7.6(dd,2H),7.85(d,2H),7.85(d,2H);MS[M-CF3COO]+:484。
实施例114
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为200mg,76%。1H-NMR(DMSO-d6):δ1.54(m,1H),1.70-1.86(m,3H),1.76(s,3H),2.13(m,1H),3.06(m,1H),3.20-3.50(m,4H),3.86(m,1H),4.05(dd,2H),5.02(m,1H),6.43(dd,1H),6.86(d,1H),7.26-7.46(m,7H),7.58-7.65(m,3H),7.70-7.72(m,1H),7.87-7.90(m,2H);MS[M-Br]+:450;mp 234℃。
实施例115
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为210mg,66%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.60-2.0(m,3H),1.76(s,3H),2.12(m,1H),3.10-3.25(m,1H),3.40-3.80(m,6H),4.0(m,1H),4.41(m,2H),4.98(m,1H),6.98-7.05(m,3H),7.27-7.46(m,6H),7.63-7.71(m,2H),7.87-7.90(m,2H);MS[M-Br]+:454;mp 202℃。
实施例116
3(R)-(9)-甲基-9[H]-芴-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为210mg,61%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.60-2.0(m,3H),1.78(s,3H),2.0-2.20(m,3H),3.0-3.10(m,1H),3.25-3.53(m,6H),3.86(m,1H),4.03(m,2H),4.98(m,1H),6.95-7.0(m,3H),7.30-7.48(m,6H),7.65-7.92(m,4H);MS[M-Br]+:468;mp 204℃。
实施例117
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为18mg,19%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.95(m,3H),1.75(s,3H),2.15(m,1H),2.9-3.1(m,4H),3.25-3.55(m,5H),3.85(m,1H),5.05(m,1H),7.25-7.55(m,9H),7.65(d,1H),7.75(d,1H),7.95(d,2H);MS[M-CF3COO]+:438。
实施例118
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-(4-氧代-4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,19%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-2.05(m,5H),1.75(s,3H),2.1(m,1H),3.0(m,1H),3.1-3.5(m,8H),3.85(m,1H),7.35-7.5(m,4H),7.55(t,2H),7.65(t,2H),7.7(d,1H),7.9(d,2H),8.0(d,2H);MS[M-CF3COO]+:480。
实施例119
1-[3-(4-氟苯氧基)丙基]-3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为23mg,23%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.95(m,3H),1.75(s,3H),2.05-2,15(m,3H),3.0(m,1H),3.25-3.5(m,6H),3.85(m,1H),4.0(t,2H),5.0(m,1H),6.95(m,2H),7.15(t,2H),7.35-7.5(m,4H),7.65(d,1H),7.75(d,1H),7.9(d,2H);MS[M-CF3COO]+:486。
实施例120
1-[3-(2,4-二氟苯氧基)丙基]-3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为20mg,19%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.95(m,3H),1.75(s,3H),2.05-2.2(m,3H),3.0(m,1H),3.25-3.55(m,6H),3.85(m,1H),4.1(t,2H),5.0(m,1H),7.05(t,1H),7.2-7.5(m,6H),7.65(d,1H),7.75/d,1H),7.9(d,2H);MS[M-CF3COO]+:504。
实施例121
3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-(3-苯基氨基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,19%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.95(m,5H),1.75(s,3H),2.1(m,1H),2.95(m,1H),3.05(m,2H),3.15-3.45(m,6H),3.8(m,1H),5.0(m,1H),5.65(t,NH),6.6(m,3H),7.1(t,2H),7.35-7.55(m,4H),7.65(d,1H),7.75(d,1H),7.9(d,2H);MS[M-CF3COO]+:467。
实施例122
1-[3-(4-羟基苯氧基)丙基]-3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为22mg,22%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.9(m,3H),1.75(s,3H),2.0-2.15(m,3H),3.0(m,1H),3.25-3.5(m,6H),3.8-3.95(m,3H),5.0(m,1H),6.7(d,1H),6.75(d,1H),7.35-7.45(m,4H),7.65(d,1H),7.75(d,1H),7.9(d,2H),9.0(s,OH);MS[M-CF3COO]+:484。
实施例123
1-(2-苄氧基乙基)-3(R)-(9-甲基-9[H]-芴-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为17mg,17%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.95(m,4H),1.75(s,3H),2.15(m,1H),3.1(m,1H),3.3-3.55(m,6H),3.8-3.95(m,3H),4.5(s,2H),5.0(m,1H),7.3-7.5(m,9H),7.6-7.7(m,2H),7.9(d,2H);MS[M-CF3COO]+:468。
实施例124
3(R)-(9,10-二氢蒽-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为420mg,89%。1H-NMR(DMSO-d6):δ1.55(m,1H),1.65-1.95(m,3H),2.15(m,1H),2.95(m,2H),3.15(m,1H),3.25-3.60(m,6H),3.85(m,1H),3.95-4.15(dd,2H,J1=1.8Hz,J2=4.2Hz),5.02(m,1H),5.25(s,1H),7.25-7.43(m,11H),7.48-7.55(m,2H);MS[M-Br]+:438;mp 216℃。
实施例125
3(R)-(9,10-二氢蒽-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为450mg,82%。1H-NMR(DMSO-d6):δ1.56(m,1H),1.65-1.95(m,3H),2.05-2.15(m,3H),3.10(m,1H),3.20-3.50(m,6H),3.80(m,1H),3.94-4.14(m,4H),5.0(m,1H),5.22(s,1H),6.94-7.0(m,3H),7.25-7.35(m,6H),7.40(m,2H),7.54-7.47(m,2H);MS[M-Br]+:468;mp 157℃。
实施例126
1-(4-苯基丁基)-3(R)-(9[H]-呫吨-9-羰氧基)-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为83mg,21%。1H-NMR(DMSO-d6):δ1.50-2.0(m,8H),2.15(m,1H),2.65(m,2H),3.05-3.65(m,7H),3.80(m,1H),5.0(m,1H),5.30(s,1H),7.10-7.45(m,11H),7.45-7.60(m,2H);MS[M-Br]+:468;mp 95℃。
实施例127
1-(2-苯氧基乙基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为300mg,73%。1H-NMR(DMSO-d6):δ1.70-2.0(m,4H),2.2(m,1H),3.20-3.80(m,7H),4.0(m,1H),4.40(m,2H),5.05(m,1H),5.30(s,1H),7.0-7.10(m,7H),7.30-7.45(m,4H),7.45-7.55(m,2H);MS[M-Br]+:456;mp 200℃。
实施例128
1-(3-苯氧基丙基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为350mg,83%。1H-NMR(DMSO-d6):δ1.70-2.0(m,4H),2.0-2.25(m,3H),3.15-3.65(m,7H),3.85-3.95(m,1H),3.95-4.10(m,2H),5.0(m,1H),5.30(s,1H),6.90-7.0(m,3H),7.10-7.25(m,4H),7.25-7.40(m,4H),7.40-7.60(m,2H);MS[M-Br]+:470;mp 184℃。
实施例129
1-苯乙基-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为100mg,44%。1H-NMR(DMSO-d6):δ1.65-2.0(m,4H),2.1(m,1H),2.9-3.05(m,2H),3.15-3.6(m,7H),3.85(m,1H),5.05(m,1H),5.3(s,1H),7.15-7.55(m,13H);MS[M-Br]+:440。
实施例130
1-(4-氧代-4-苯基丁基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法d和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.65-2.05(m,6H),2.1(m,1H),3.1-3.55(m,9H),3.8(m,1H),5.05(m,1H),5.25(s,1H),7.1-7.3(m,4H),7.35(t,2H),7.45-7.6(m,4H),7.7(d,1H),8.0(d,1H);MS[M-CF3COO]+:482。
实施例131
1-[3-(4-氟苯氧基)丙基]-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法d和b,合成标题化合物。最终步骤的产量为18mg,18%。1H-NMR(DMSO-d6):δ1.7-2.1(m,6H),2.15(m,1H),3.1-3.5(m,7H),3.8(m,1H),4.0(t,2H),5.0(m,1H),5.3(s,1H),6.95(m,2H),7.1-7.3(m,6H),7.4(t,2H),7.5(dd,2H);MS[M-CF3COO]+:488。
实施例132
1-[3-(2,4-二氟苯氧基)丙基]-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法d和b,合成标题化合物。最终步骤的产量为14mg,14%。1H-NMR(DMSO-d6):δ1.65-1.95(m,4H),2.05-2.2(m,3H),3.1-3.55(m,7H),3.8(m,1H),4.05(t,2H),5.0(m,1H),5.3(s,1H),7.05(t,1H),7.1-7.55(m,10H);MS[M-CF3COO]+:506。
实施例133
1-(3-苯基氨基丙基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法d和b,合成标题化合物。最终步骤的产量为17mg,17%。1H-MR(DMSO-d6):δ1.65-2.0(m,6H),2.15(m,1H),3.0-3.5(m,9H),1.75(m,1H),5.0(m,1H),5.3(s,1H),6.65(t,NH),6.55(m,3H),7.05-7.3(m,6H),7.35-7.55(m,4H);MS[M-CF3COO]+:469。
实施例134
1-[3-(4-羟基苯氧基)丙基]-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法d和b,合成标题化合物。最终步骤的产量为21mg,20%。1H-NMR(DMSO-d6):δ1.7-2.1(m,6H),2.15(m,1H),3.1-3.5(m,7H),3.7-3.95(m,3H),5.0(m,1H),5.3(s,1H),6.7(d,2H),6.75(d,2H),7.1-7.3(m,4H),7.35-7.55(m,4H),9.0(s,OH);MS[M-CF3COO]+:486。
实施例135
1-(2-苄氧基乙基)-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法d和b,合成标题化合物。最终步骤的产量为16mg,16%。1H-NMR(DMSO-d6):δ1.65-1.95(m,4H),2.1(m,1H),3.1-3.9(m,10H),4.5(s,2H),5.0(m,1H),5.3(s,1H),7.15(m,4H),7.3-7.5(m,7H),7.55(t,2H);MS[M-CF3COO]+:470。
实施例136
3(R)-(9-羟基-9[H]-呫吨-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为340mg,71%。1H-NMR(DMSO-d6):δ1.30(m,1H),1.65(m,1H),1.70-1.95(m,2H),1.95-2.10(m,3H),2.70(m,1H),2.90(m,1H),3.2-3.5(m,5H),3.80(m,1H),4.0(t,2H),5.05(m,1H),6.90-7.0(m,3H),7.20-7.35(m,7H),7.40-7.46(m,2H),7.65-7.70(m,2H);MS[M-Br]+:486;mp 219℃。
实施例137
3(R)-(9-羟基-9[H]-呫吨-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为290mg,64%。1H-NMR(DMSO-d6):δ1.32(m,1H),1.65(m,1H),1.70-1.95(m,2H),2.1(m,1H),2.75-2.90(m,3H),3.05(m,1H),3.30-3.50(m,5H),3.82(m,1H),5.05(m,1H),7.20-7.40(m,10H),7.40-7.50(m,2H),7.65-7.70(m,2H);MS[M-Br]+:456;mp 221℃。
实施例138
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(3-噻吩-2-基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为310mg,97%。1H-NMR(DMSO-d6):δ1.30(m,1H),1.62(m,1H),1.70-1.90(m,4H),2.05(m,1H),2.60(m,1H),2.75-2.85(m,4H),3.15(m,2H),3.25-3.40(m,2H),3.75(m,1H),5.0(m,1H),6.93(m,1H),7.0(m,1H),7.14-7.26(m,5H),7.36-7.45(m,3H),7.63-7.67(m,2H);MS[M-Br]+:476;mp111℃。
实施例139
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(3-苯基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为85mg,41%。1H-NMR(DMSO-d6):δ1.30(m,1H),1.65(m,1H),1.70-1.95(m,2H),2.05(m,1H),2.5-2.6(m,2H),2.80(m,1H),3.05-3.75(m,7H),5.05(m,1H),7.1-7.45(m,12H),7.65-7.70(m,2H);MS[M-CF3COO]+:470。
实施例140
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为84mg,38%。1H-NMR(DMSO-d6):δ1.30(m,1H),1.4-1.85(m,7H),2.05(m,1H),2.5-2.6(m,2H),2.80(m,1H),3.05-3.4(m,6H),3.7(m,1H),5.05(m,1H),7.15-7.35(m,10H),7.4(m,1H),7.65(m,2H);MS[M-CF3COO]+:484。
实施例141
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(2-噻吩-2-基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为81mg,39%。1H-NMR(DMSO-d6):δ1.30(m,1H),1.6(m,1H),1.7-1.9(m,2H),2.05(m,1H),2.75(m,1H),3.0(m,1H),3.1-3.2(m,2H),3.3-3.6(m,5H),3.8(m,1H),5.05(m,1H),6.95-7.0(m,2H),7.15-7.3(m,5H),7.45(m,3H),7.65(m,2H);MS[M-CF3COO]+:462。
实施例142
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(4-苯氧基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为83mg,37%。1H-NMR(DMSO-d6):δ1.3(m,1H),1.5-1.9(m,7H),2.05(m,1H),2.6(m,1H),2.8(m,1H),3.1-3.45(m,7H),3.75(m,1H),4.0(m,2H),5.05(m,1H),6.95-7.0(m,3H),7.15-7.45(m,9H),7.65(m,2H);MS[M-CF3COO]+:500。
实施例143
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(2-苯氧基乙基)-1-氟鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为102mg,48%。1H-NMR(DMSO-d6):δ1.3(m,1H),1.55-1.95(m,3H),2.05(m,1H),2.8(m,1H),3.1(m,1H),3.35-3.65(m,5H),3.9(m,1H),4.35(m,2H),5.05(m,1H),6.95(d,2H),7.0-7.1(m,2H),7.2(m,4H),7.3-7.45(m,4H),7.6(t,2H);MS[M-CF3COO]+:472。
实施例144
1-[3-(4-氟苯氧基)丙基]-3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为99mg,44%。1H-NMR(DMSO-d6):δ1.3(m,1H),1.6(m,1H),1.7-2.0(m,4H),2.05(m,1H),2.7(m,1H),2.9(m,1H),3.2-3.5(m,5H),3.75-3.85(m,1H),3.95(m,2H),5.0(m,1H),6.95(m,2H),7.1-7.3(m,7H),7.45(t,2H),7.65(t,2H);MS[M-CF3COO]+:504。
实施例145
3(R)-(9-羟基-9H-呫吨-9-羰氧基)-1-(3-苯基烯丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为25mg,12%。1H-NMR(DMSO-d6):δ1.25-1.30(m,1H),1.55-1.95(m,3H),2.10(m,1H),2.65-2.75(m,1H),2.9(m,1H),3.25-3.50(m,2H),3.75-3.8(m,1H),3.95(m,2H),4.2(d,1H),5.0(m,1H),6.35(m,1H),6.80(d,1H),7.05-7.50(m,8H),7.60(m,4H);MS[M-CF3COO]+:468。
实施例146
3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法c和a,合成标题化合物。最终步骤的产量为110mg。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.75-1.95(m,2H),1.9(s,3H),2.05-2.15(m,3H),1.8(m,1H),3.15(m,2H),3.25-3.5(m,5H),3.85(m,1H),4.0(t,2H),5.05(m,1H),6.95-7.0(m,3H),7.15-7.2(m,4H),7.3-7.4(m,4H),7.45(d,1H),7.55(d,1H);MS[M-Br]+:484;mp 195℃。
实施例147
3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,20%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.8-1.95(m,2H),1.9(s,3H),2.15(m,1H),2.8-2.95(m,3H),3.15(d,1H),3.3-3.5(m,5H),4.9(m,1H),5.1(m,1H),7.15(m,4H),7.25-7.4(m,7H),7.45(d,1H),7.55(d,1H);MS[M-CF3COO]+:454。
实施例148
3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-(2-苯氧基乙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为24mg,24%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.8-1.95(m,2H),1.9(s,3H),2.15(m,1H),2.95(m,1H),3.25(m,1H),3.4-3.65(m,5H),3.85(m,1H),4.35(t,2H),5.05(m,1H),6.95(d,2H),7.05(t,2H),7.15(m,3H),7.25-7.45(m,6H);MS[M-CF3COO]+:470。
实施例149
3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-(4-氧代-4-苯基丁基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,19%。1H-MR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.75-1.95(m,7H),2.15(m,1H),2.8(m,1H),3.05-3.25(m,4H),3.3-3.5(m,4H),3.85(m,1H),5.05(m,1H),7.15(m,4H),7.35(t,2H),7.45-7.6(m,4H),7.7(t,1H),8.0(d,2H);MS[M-CF3COO]+:496。
实施例150
1-[3-(4-氟苯氧基)丙基]-3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为25mg,24%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.75-1.95(m,2H),1.9(s,3H),1.95-2.1(m,2H),2.15(m,1H),2.8(m,1H),3.1(d,1H),3.25-3.5(m,5H),3.8(m,1H),4.0(t,2H),5.05(m,1H),6.95(m,2H),7.15(m,6H),7.35(t,2H),7.5(dd,2H);MS[M-CF3COO]+:502。
实施例151
1-[3-(2,4-二氟苯氧基)丙基]-3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.75-1.95(m,2H),1.9(s,3H),2.0-2.15(m,3H),2.8(m,1H),3.1(d,1H),7.05(t,1H),7.1-7.4(m,8H),7.5(dd,2H);MS[M-CF3COO]+:520。
实施例152
3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-(3-苯基氨基丙基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为16mg,15%。1H-NMR(DMSO-d6):δ1.35(m,1H),1.6(m,1H),1.7-1.9(m,4H),1.9(s,3H),2.1(m,1H),2.7(m,1H),2.95-3.05(m,3H),3.1-3.4(m,6H),3.75(m,1H),5.0(m,1H),5.6(m,1H),6.55(m,3H),7.05-7.15(m,6H),7.3(m,2H),7.45(t,2H);MS[M-CF3COO)+:483。
实施例153
1-[3-(4-羟基苯氧基)丙基]-3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为19mg,18%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),2.75-2.05(m,4H),1.9(s,3H),2.15(m,1H),2.8(m,1H),3.1(d,1H),3.25-3.5(m,5H),3.8-3.95(m,3H),5.05(m,1H),6.65-6.8(m,4H),7.2(m,4H),7.35(t,2H),7.5(m,2H),9.0(s,OH);MS[M-CF3COO]+:500。
实施例154
1-(2-苄氧基乙基)-3(R)-(9-甲基-9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;三氟乙酸盐
按照方法c和b,合成标题化合物。最终步骤的产量为14mg,14%。1H-NMR(DMSO-d6):δ1.4(m,1H),1.65(m,1H),1.75-1.95(m,2H),1.9(s,3H),2.1(m,1H),2.9(m,1H),3.2-3.5(m,6H),3.75-3.95(m,3H),4.5(s,2H),5.05(m,1H),7.15(m,4H),7.3-7.5(m,9H);MS[M-CF3COO]+:484。
实施例155
1-(3-苯氧基丙基)-3(R)-(9[H]-噻吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为323mg,50%。1H-NMR(DMSO-d6):δ1.35(m,1H),1.65(m,1H),1.70-1.95(m,2H),2.0-2.2(m,3H),2.75-2.90(m,1H),3.12(m,1H),3.25-3.50(m,5H),3.80(m,1H),4.0(t,2H),5.0(m,1H),5.6(s,1H),6.94-7.0(m,3H),7.22-7.41(m,6H),7.45-7.64(m,4H);MS[M-Br]+:486;mp 157℃。
实施例156
1-(3-苯基烯丙基)-3(R)-(10,11-二氢-5H-二苯并[a,d]环庚烯-5-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为250mg,94%。1H-NMR(CDCl3):δ1.50-1.60(m,1H),1.60-1.80(m,1H),1.90(m,2H),2.30(m,1H),2.65-2.80(m,2H),2.90-3.20(m,3H),3.50(d,1H),3.60-3.90(m,3H),4.20(m,1H),4.35-4.60(双dd,2H),5.10(m,1H),5.15(s,1H),6.05(dd,1H),6.90-7.0(m,2H),7.0-7.5(m,11H);MS[M-Br]+:464;mp 132℃。
实施例157
1-(3-苯氧基丙基)-3(R)-(10,11-二氢-5H-二苯并[a,d]环庚烯-5-羰氧基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为290mg,94%。1H-NMR(CDCl3):δ1.45-1.60(m,1H),1.65-1.80(m,1H),1.80-2.0(m,2H),2.0-2.20(m,3H),2.80-3.0(m,3H),3.15-3.30(m,2H),3.30-3.45(d,1H),3.45-3.80(m,5H),3.85-4.0(m,2H),4.20(m,1H),5.10(m,1H),5.20(s,1H),6.80-6.90(d,2H),6.90-7.0(t,1H),7.10-7.30(m,8H),7.40(m,2H);MS[M-Br]+:482;mp 182℃。
实施例158
3(R)-(5[H]-二苯并[a,d]环庚烯-5-羰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为180mg,56%。1H-NMR(DMSO-d6):δ1.2(m,1H),1.6(m,1H),1.7-1.9(m,2H),1.95(m,1H),2.1(m,2H),2.8(m,1H),2.95(d,1H),3.25-3.45(m,5H),3.8(m,1H),4.05(t,2H),4.9(m,1H),5.45(s,1H),6.9-7.1(m,5H),7.3-7.5(m,9H),7.55(d,2H);MS[M-Br]+:480;mp 111℃。
实施例159
3(R)-(5[H]-二苯并[a,d]环庚烯-5-羰氧基)-1-苯乙基-1-氮鎓双环[2.2.2]辛烷;溴化物
按照方法d和a,合成标题化合物。最终步骤的产量为210mg,68%。1H-NMR(DMSO-d6):δ1.2(m,1H),1.7-1.9(m,2H),2.0(m,1H),2.85-3.1(m,4H),3.3-3.5(m,5H),3.85(m,1H),4.95(m,1H),5.45(s,1H),7.05(m,2H),7.25-7.5(m,11H),7.55(m,2H);MS[M-Br]+:450;mp248℃。
实施例160-164阐明本发明的药用组合物和它们的制备方法。
实施例160
药用组合物的制备:片剂
制剂:
本发明的化合物……………………………… 5.0mg
乳糖…………………………………………… 113.6mg
微晶纤维素…………………………………… 28.4mg
轻二氧化硅…………………………………… 1.5mg
硬脂酸镁……………………………………… 1.5mg
使用混合机,将15g本发明化合物与340.8g乳糖和85.2g微晶纤维素混合。使用滚压机使混合物经受模压,得到饼样压实的物料。使用锤磨机,把饼样压实的物料研磨成粉,通过20目筛筛分粉状物料。将一份4.5g轻二氧化硅和4.5g硬脂酸镁加入到已筛分的物料中,混合。将混合的产物经受配有直径7.5mm冲模/冲压系统的压片机,由此得到3,000片,每片重150mg。
实施例161
药用组合物的制备:包衣片剂
制剂:
本发明组合物 ………………………………… 5.0mg
乳糖 …………………………………………… 95.2mg
玉米淀粉 ……………………………………… 40.8mg
聚乙烯吡咯烷酮K25…………………………… 7.5mg
硬脂酸镁 ……………………………………… 1.5mg
羟基丙基纤维素 ……………………………… 2.3mg
聚乙二醇6000 ………………………………… 0.4mg
二氧化钛 ……………………………………… 1.1mg
纯滑石粉 ……………………………………… 0.7mg
使用流化床制粒机,将15g本发明化合物与285.6g乳糖和122.4g玉米淀粉混合。另外,将22.5g聚乙烯吡咯烷酮溶于127.5g水中,制备粘合溶液。使用流化床制粒机,将粘合溶液喷雾到以上混合物中,得到颗粒。将一份4.5g硬脂酸镁加入到已得到的颗粒中,混合。将得到的混合物经受配有直径6.5mm冲模/冲压两面凹的系统的压片机,结果得到3,000片,每片重150mg。
另外,通过将6.9g羟基丙基甲基纤维素2910、1.2g聚乙二醇6000、3.3g二氧化钛和2.1g纯滑石粉悬浮于72.6g水中,制备包衣溶液。使用高速包衣机(High Coated),用包衣溶液包衣以上制备的3,000片剂,得到薄膜包衣片剂,每片重154.5mg。
实施例162
药用组合物的制备:液体吸入剂
制剂:
本发明组合物………………………………… 400μg
生理盐水……………………………………… 1ml
将40mg份本发明化合物溶于90ml生理盐水中,用相同的盐水溶液将溶液调至总体积100ml,以1ml份分散于1ml容积的安瓿中,然后在115℃下灭菌30分钟,得到液体吸入剂。
实施例163
药用组合物的制备:粉末吸入剂
制剂:
本发明组合物……………………………… 200μg
乳糖………………………………………… 4,000μg
将20g份本发明化合物与400g乳糖均匀混合,将200mg份混合物填充至外用的粉末吸入器中以产生粉末吸入剂。
实施例164
药用组合物的制备:吸入气溶胶
制剂:
本发明组合物 …………………………………… 200μg
脱水(无水)乙醇USP……………………………… 8,400μg
1,1,1,2-四氟乙烷(HFC-134A)……………… 46,810μg
通过将0.0480g本发明化合物溶于2.0160g乙醇中,制备活性成分浓缩液。将浓缩液加入到合适的填充装置中。把活性成分浓缩液分散于气溶胶容器中,用氮气或HFC-134A蒸汽(清洗成分应不含有大于1ppm的氧)清洗容器的液面上空间且用阀密封。然后将11.2344g的HFC-134A抛射剂加压填充到密封容器中。
Claims (8)
1.一种化合物,其为3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓双环[2.2.2]辛烷;X-或者1-苯乙基-3(R)-(9[H]-呫吨-9-羰氧基)-1-氮鎓双环[2.2.2]辛烷;X-,其中所述X-表示单或多价酸的药学上可接受的阴离子。
2.权利要求1的化合物,其中X-是氯化物、溴化物、碘化物、硫酸盐、硝酸盐、磷酸盐、乙酸盐、三氟乙酸盐、马来酸盐、富马酸盐、枸橼酸盐、草酸盐、琥珀酸盐、酒石酸盐、苹果酸盐、扁桃酸盐、甲磺酸盐或对甲苯磺酸盐。
3.一种药物组合物,它包含与药学上可接受的载体或稀释剂混合的权利要求1或2的化合物。
4.权利要求3的药物组合物,其还包含β2激动剂。
5.权利要求3的药物组合物,其还包含甾体。
6.权利要求3的药物组合物,其还包含抗过敏药。
7.权利要求3的药用组合物,其还包含磷酸二酯酶IV抑制剂。
8.权利要求4-7中任一项的组合物在制备用于治疗慢性阻塞性肺病、慢性支气管炎、支气管过敏反应、哮喘或鼻炎的药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009901580A ES2165768B1 (es) | 1999-07-14 | 1999-07-14 | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
ESP9901580 | 1999-07-14 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008127549A Division CN1272334C (zh) | 1999-07-14 | 2000-07-07 | 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1824664A true CN1824664A (zh) | 2006-08-30 |
CN100451018C CN100451018C (zh) | 2009-01-14 |
Family
ID=8309225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008127549A Expired - Lifetime CN1272334C (zh) | 1999-07-14 | 2000-07-07 | 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 |
CNB2006100068921A Expired - Lifetime CN100451018C (zh) | 1999-07-14 | 2000-07-07 | 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008127549A Expired - Lifetime CN1272334C (zh) | 1999-07-14 | 2000-07-07 | 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 |
Country Status (39)
Country | Link |
---|---|
US (16) | US6750226B2 (zh) |
EP (1) | EP1200431B3 (zh) |
JP (2) | JP4030040B2 (zh) |
KR (3) | KR100854321B1 (zh) |
CN (2) | CN1272334C (zh) |
AR (1) | AR029760A1 (zh) |
AT (1) | ATE235492T1 (zh) |
AU (1) | AU2005202144B2 (zh) |
BE (1) | BE2013C001I2 (zh) |
BG (1) | BG65565B1 (zh) |
BR (1) | BRPI0012434B8 (zh) |
CA (1) | CA2381165C (zh) |
CO (1) | CO5200759A1 (zh) |
CY (1) | CY2013001I1 (zh) |
CZ (1) | CZ304292B6 (zh) |
DE (2) | DE60001840D1 (zh) |
DK (1) | DK1200431T6 (zh) |
EE (1) | EE04915B3 (zh) |
EG (1) | EG24066A (zh) |
ES (2) | ES2165768B1 (zh) |
FR (1) | FR13C0001I2 (zh) |
HK (1) | HK1042487B (zh) |
HU (1) | HU228594B1 (zh) |
IL (1) | IL147533A0 (zh) |
LU (1) | LU92132I2 (zh) |
MY (1) | MY126959A (zh) |
NO (2) | NO329484B3 (zh) |
PE (1) | PE20010397A1 (zh) |
PL (1) | PL204024B1 (zh) |
PT (1) | PT1200431E (zh) |
RU (2) | RU2264401C3 (zh) |
SI (1) | SI1200431T1 (zh) |
SK (1) | SK287480B6 (zh) |
TR (1) | TR200200768T2 (zh) |
TW (1) | TWI284644B (zh) |
UA (1) | UA73509C2 (zh) |
UY (2) | UY26244A1 (zh) |
WO (1) | WO2001004118A2 (zh) |
ZA (1) | ZA200200232B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102112474B (zh) * | 2008-08-08 | 2014-01-29 | 奇斯药制品公司 | 奎宁环碳酸酯衍生物及其药用组合物 |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
AR028948A1 (es) * | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
IL156499A0 (en) * | 2000-12-22 | 2004-01-04 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as m3 antagonists |
EP1353919B1 (en) * | 2000-12-28 | 2006-07-26 | Almirall Prodesfarma AG | Novel quinuclidine derivatives and medicinal compositions containing the same |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US7361787B2 (en) | 2001-09-14 | 2008-04-22 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
IL162596A0 (en) * | 2001-12-20 | 2005-11-20 | S A L V A T Lab Sa | 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists |
US7405224B2 (en) | 2002-01-31 | 2008-07-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions |
DE10203753A1 (de) * | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
TW200410951A (en) * | 2002-08-06 | 2004-07-01 | Glaxo Group Ltd | M3 muscarinic acetylcholine receptor antagonists |
TWI295669B (en) | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
EP1590345A1 (en) * | 2002-12-23 | 2005-11-02 | Ranbaxy Laboratories, Ltd. | Xanthine derivatives as muscarinic receptor antagonists |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
CN100445281C (zh) * | 2003-05-02 | 2008-12-24 | 诺瓦提斯公司 | 与毒蕈碱性m3受体结合的奎宁环衍生物 |
WO2004106333A1 (en) | 2003-05-28 | 2004-12-09 | Theravance, Inc. | Azabicycloalkane compounds as muscarinic receptor antagonists |
JP2007524641A (ja) | 2003-07-11 | 2007-08-30 | セラヴァンス, インコーポレーテッド | 置換4−アミノ−1−ベンジルピペリジン化合物 |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
AR045913A1 (es) * | 2003-07-17 | 2005-11-16 | Glaxo Group Ltd | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina |
TW200519109A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
TW200519108A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
US20050026887A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
AU2004262901B2 (en) * | 2003-07-29 | 2010-05-13 | Boehringer Ingelheim International Gmbh | Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation |
US20050026886A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
JP2007500149A (ja) * | 2003-07-29 | 2007-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患を治療するためのpdeiv阻害剤と抗コリン作用剤を含む薬剤 |
EP1651270B1 (en) * | 2003-07-29 | 2007-03-21 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising betamimetics and an anticholinergic |
US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
CA2534120C (en) * | 2003-07-31 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
US20050025718A1 (en) * | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
MY143366A (en) | 2003-10-14 | 2011-04-29 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
MXPA06004242A (es) * | 2003-10-17 | 2006-06-28 | Glaxo Group Ltd | Antagonistas del receptor muscarinico de la acetilcolina. |
TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
US20090253908A1 (en) * | 2004-03-11 | 2009-10-08 | Glaxo Group Limited | Novel m3 muscarinic acetylchoine receptor antagonists |
ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
EP1725564A4 (en) | 2004-03-17 | 2007-09-12 | Glaxo Group Ltd | ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR |
MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
WO2005112644A2 (en) * | 2004-05-13 | 2005-12-01 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
ES2317245T3 (es) * | 2004-05-31 | 2009-04-16 | Laboratorios Almirall, S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
DE602004018844D1 (de) * | 2004-06-16 | 2009-02-12 | Ranbaxy Lab Ltd | Als antagonisten des muscarinrezeptors geeignete xanthinderivate |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
GB0418278D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Medicament dispenser |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
EP1841780B1 (en) | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
WO2006094924A2 (en) * | 2005-03-09 | 2006-09-14 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
JP2008534611A (ja) | 2005-03-30 | 2008-08-28 | シェーリング コーポレイション | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
JP2009503101A (ja) * | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | M3ムスカリン性アセチルコリン受容体アンタゴニスト |
TW200738634A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
EP1937267A4 (en) * | 2005-08-02 | 2009-08-26 | Glaxo Group Ltd | M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS |
BRPI0614290A2 (pt) * | 2005-08-08 | 2011-03-22 | Argenta Discovery Ltd | derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos |
WO2007022351A2 (en) * | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
TW200744612A (en) * | 2005-08-26 | 2007-12-16 | Astrazeneca Ab | New combination |
AR058104A1 (es) | 2005-10-21 | 2008-01-23 | Novartis Ag | Compuestos organicos |
PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
CA2635649A1 (en) * | 2006-01-06 | 2007-07-12 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and andolast |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
MX2008013411A (es) | 2006-04-20 | 2008-11-04 | Glaxo Group Ltd | Nuevos compuestos. |
JP5373599B2 (ja) | 2006-04-21 | 2013-12-18 | ノバルティス アーゲー | アデノシンa2a受容体アゴニストとして使用するためのプリン誘導体 |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
WO2008008021A1 (en) * | 2006-07-14 | 2008-01-17 | Astrazeneca Ab | Inhalation system and delivery device for the administration of a drug in the form of dry powder. |
JP2009543860A (ja) | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
ES2298049B1 (es) * | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
JP2010504933A (ja) | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
GB0622827D0 (en) | 2006-11-15 | 2006-12-27 | Glaxo Group Ltd | Sheet driver for use in a drug dispenser |
JP2010513277A (ja) * | 2006-12-13 | 2010-04-30 | ギリード・サイエンシズ・インコーポレーテッド | COPDおよび慢性気管支炎の治療のためのムスカリン受容体アンタゴニストおよびβ−アゴニストの共通プロドラッグとしてのモノホスフェート |
ATE493174T1 (de) | 2007-01-10 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
MX2009008825A (es) * | 2007-02-21 | 2009-10-12 | Almirall Sa | Nuevos metodos de terapia anticolinergica. |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
KR20100005730A (ko) | 2007-05-07 | 2010-01-15 | 노파르티스 아게 | 유기 화합물 |
JP5656288B2 (ja) | 2007-09-07 | 2015-01-21 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物 |
CA2608561A1 (en) * | 2007-10-29 | 2009-04-29 | Carl Paluszkiewicz | Motorcycle wind deflector accessory support |
ES2602331T3 (es) | 2007-12-10 | 2017-02-20 | Novartis Ag | Pirazin-carboxamidas de tipo amilorida como bloqueantes de ENaC |
US8017617B2 (en) * | 2007-12-14 | 2011-09-13 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
US20090215734A1 (en) * | 2008-02-26 | 2009-08-27 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
US20100055045A1 (en) * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
MX2010012189A (es) | 2008-05-13 | 2011-03-02 | Astrazeneca Ab | Derivados de quinuclidina como antagonistas del receptor m3 muscarinico. |
GB0808707D0 (en) * | 2008-05-13 | 2008-06-18 | Argenta Discovery Ltd | New compounds 275 |
AU2009325091A1 (en) | 2008-05-23 | 2010-06-17 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein inhibitor |
CN102105448B (zh) | 2008-05-27 | 2013-11-13 | 阿斯利康(瑞典)有限公司 | 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途 |
US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
MX2010013675A (es) | 2008-06-10 | 2011-02-15 | Novartis Ag | Derivados de pirazina como bloqueadores del canal de sodio epitelial. |
US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
EP2391366B1 (en) | 2009-01-29 | 2012-11-28 | Novartis AG | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
EA201171144A1 (ru) | 2009-03-19 | 2012-04-30 | Мерк Шарп Энд Домэ Корп. | ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
US20120004282A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp, | RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたアポトーシスシグナル調節キナーゼ1(ASK1)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
PT2417106T (pt) | 2009-04-09 | 2017-02-13 | Novartis Ag | Processo para preparação de sais de pirrolidínio |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
UY32571A (es) | 2009-04-24 | 2010-11-30 | Glaxo Group Ltd | Compuestos derivados de pirazol amida |
CA2759476C (en) | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
PL2435025T3 (pl) | 2009-05-29 | 2017-08-31 | Pearl Therapeutics, Inc. | Dostarczanie substancji czynnych do dróg oddechowych |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
GB0910537D0 (en) | 2009-06-18 | 2009-07-29 | Ivax Pharmaceuticals Ireland | Inhaler |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
KR20120089463A (ko) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | 헤테로시클릭 옥심 화합물 |
EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0919465D0 (en) | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
DK2614058T3 (en) | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
ES2532213T3 (es) | 2010-10-21 | 2015-03-25 | Glaxo Group Limited | Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
CN103492384B (zh) | 2011-02-25 | 2016-05-11 | 诺华股份有限公司 | 作为trk抑制剂的化合物和组合物 |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
BR112014006223A8 (pt) | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
JP5886433B2 (ja) | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
AU2012352153B2 (en) | 2011-12-13 | 2018-07-26 | Veracyte, Inc. | Cancer diagnostics using non-coding transcripts |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
CA2893663A1 (en) * | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Phenylethylpyridine derivatives as pde4-inhibitors |
HRP20221034T1 (hr) | 2012-12-17 | 2022-11-11 | Almirall S.A. | Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
TR201902687T4 (tr) | 2013-03-15 | 2019-03-21 | Pearl Therapeutics Inc | İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler. |
EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
CA2921621C (en) * | 2013-07-13 | 2018-08-28 | Beijing Fswelcome Technology Development Co., Ltd | Quinine compounds, and optical isomers, preparation method and medical use thereof |
US9657007B2 (en) | 2013-09-22 | 2017-05-23 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
JP6475707B2 (ja) | 2013-10-17 | 2019-02-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
CZ306791B6 (cs) | 2013-10-29 | 2017-07-12 | Zentiva, K.S. | Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
CN103755699A (zh) * | 2014-01-06 | 2014-04-30 | 万特制药(海南)有限公司 | 一种2-羟基-2,2-二噻吩-2-基乙酸-1-氮杂二环[2,2,2]辛-3(r)-基酯制备方法 |
CN103755698A (zh) * | 2014-01-06 | 2014-04-30 | 万特制药(海南)有限公司 | 一锅法制备阿地溴铵的工艺 |
CZ2014188A3 (cs) | 2014-03-26 | 2015-10-07 | Zentiva, K.S. | Nové formy aclidinium chloridu a způsob jejich přípravy |
JP6517319B2 (ja) | 2014-03-28 | 2019-05-22 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc | 置換されたヘテロアリール化合物および使用方法 |
MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
ES2667424T3 (es) | 2014-04-24 | 2018-05-10 | Novartis Ag | Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa |
KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
EA201692111A1 (ru) | 2014-05-12 | 2017-08-31 | Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
JP6693943B2 (ja) * | 2015-03-02 | 2020-05-13 | 株式会社Lttバイオファーマ | キヌクリジン誘導体 |
PT108370B (pt) | 2015-03-30 | 2018-10-25 | Hovione Farm S A | Processo de preparação de brometo de aclidínio |
WO2016162878A1 (en) * | 2015-04-04 | 2016-10-13 | Harman Finochem Limited | An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i |
CZ2015257A3 (cs) | 2015-04-16 | 2016-10-26 | Zentiva, K.S. | Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu |
CN105085355B (zh) * | 2015-06-25 | 2017-11-14 | 御盛隆堂药业有限责任公司 | 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用 |
EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
WO2018094392A1 (en) | 2016-11-21 | 2018-05-24 | Lupin Inc. | Medicament dispenser |
GB201700727D0 (en) | 2017-01-16 | 2017-03-01 | Teva Pharma | Inhalers and airflow adaptors therefor |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190076607A1 (en) | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
WO2019129801A1 (en) | 2017-12-28 | 2019-07-04 | Linnea S.A. | Process for the purification of methyl-2,2-dithienylglycolate |
AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2020058823A1 (en) | 2018-09-17 | 2020-03-26 | Lupin, Inc. | Dose indicator assembly for a medicament dispenser |
CA3139634A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
CA3146109A1 (en) | 2019-08-28 | 2021-03-04 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CN115916305A (zh) | 2020-03-25 | 2023-04-04 | 陆品公司 | 多载体药物分配器 |
WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
MX2023000955A (es) | 2020-07-23 | 2023-04-26 | Lupin Inc | Conjuntos contadores de dosis para dispensadores de medicamentos. |
Family Cites Families (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091570A (en) | 1960-08-08 | 1963-05-28 | Lakeside Lab Inc | Antidepressant: 3-pyrrolidyl glycolates |
GB1219606A (en) * | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
FR2414044A1 (fr) | 1978-01-10 | 1979-08-03 | Pharmindustrie | Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments |
IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
IT1116047B (it) | 1979-04-27 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
FR2539135B1 (fr) | 1983-01-11 | 1986-02-28 | Essilor Int | Hydrogels de polyurethane et procede de fabrication |
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
US4675326A (en) * | 1985-05-08 | 1987-06-23 | Gabriel Amitai | Bisquaternary antidotes |
US4855290A (en) | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
GB8718345D0 (en) * | 1987-08-03 | 1987-09-09 | Fordonal Sa | N-substituted benzamides |
US4843074A (en) | 1988-05-17 | 1989-06-27 | Marion Laboratories, Inc. | 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts |
DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
GB8923590D0 (en) * | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
US5507281A (en) | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
ES2161211T3 (es) | 1990-09-06 | 2001-12-01 | Pfizer | Broncodilatadores antimuscarinicos. |
US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
WO1992004928A2 (en) | 1990-09-26 | 1992-04-02 | Pharbita B.V. | Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber |
GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
US5263480A (en) | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
GB9119705D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic compounds |
DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
RO117414B1 (ro) | 1992-12-09 | 2002-03-29 | Jager Paul D Waterbury | Compozitie farmaceutica de aerosol in solutie |
NZ259241A (en) | 1992-12-18 | 1996-12-20 | Schering Corp | Inhaler including a counter ring, a nozzle to break powder agglomerates and spring-biased, bi-directionally rotatable metering plate and powder house |
WO1995021820A1 (fr) | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
US5569447A (en) * | 1994-04-19 | 1996-10-29 | The United States Of America Represented By The Secretary Department Of Health And Human Services | Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives |
EP0772655B1 (en) | 1994-07-29 | 2000-03-01 | Minnesota Mining And Manufacturing Company | Acrylic syrup curable to a crosslinked viscoelastomeric material |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
SK284447B6 (sk) | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Merací dávkovací inhalátor |
ES2168488T3 (es) | 1995-06-21 | 2002-06-16 | Sofotec Gmbh & Co Kg | Cartucho de polvo farmaceutico con dispositivo dosificador integrado e inhalador para medicamentos en polvo. |
WO1997001337A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
DE19528145A1 (de) | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
FR2756739B1 (fr) * | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6423298B2 (en) | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
IL140353A0 (en) | 1998-06-18 | 2002-02-10 | Boehringer Ingelheim Pharma | Pharmaceutical formulations for aerosols with two or more active substances |
ITMI981671A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
PT1102579E (pt) | 1998-08-04 | 2003-07-31 | Jago Res Ag | Formulacoes de aerossol medicinais |
US5962505A (en) | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
DE19847968A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US7214687B2 (en) * | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
GB9928311D0 (en) | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
FR2803378B1 (fr) | 1999-12-29 | 2004-03-19 | Valeo Climatisation | Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile |
WO2001054728A1 (en) | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
EA005028B1 (ru) | 2000-01-31 | 2004-10-28 | Пфайзер Продактс Инк. | Пиримидинкарбоксамиды, используемые в качестве ингибиторов изозимов pde4 |
CA2404226A1 (en) | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
GB0008485D0 (en) | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
US6777132B2 (en) | 2000-04-27 | 2004-08-17 | Valence Technology, Inc. | Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
JP5392880B2 (ja) | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
AR029984A1 (es) | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
US6852728B2 (en) | 2000-10-14 | 2005-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |
US20020137764A1 (en) | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
US20020193393A1 (en) | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
US6608054B2 (en) | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
US6620438B2 (en) | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
US20020122773A1 (en) | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
US20020151541A1 (en) | 2000-10-31 | 2002-10-17 | Michel Pairet | Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
JP2004512359A (ja) | 2000-10-31 | 2004-04-22 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物 |
US20020193392A1 (en) | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
DE10056104A1 (de) | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
US20100310477A1 (en) | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
IL156499A0 (en) | 2000-12-22 | 2004-01-04 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as m3 antagonists |
EP1353919B1 (en) | 2000-12-28 | 2006-07-26 | Almirall Prodesfarma AG | Novel quinuclidine derivatives and medicinal compositions containing the same |
US20020189610A1 (en) | 2001-02-01 | 2002-12-19 | Karl-Heinz Bozung | Pharmaceutical compositions containing an ipratropium salt and a betamimetic |
US20020179087A1 (en) | 2001-02-01 | 2002-12-05 | Karl-Heinz Bozung | Pharmaceutical compositions containing an oxitropium salt and a betamimetic |
DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030216329A1 (en) | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
ATE347361T1 (de) | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
NZ529335A (en) | 2001-05-25 | 2005-09-30 | Pfizer | A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
GB0115181D0 (en) | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
US6919325B2 (en) | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
US6680345B2 (en) | 2001-09-14 | 2004-01-20 | Boehringer Ingelheim Pharma Kg | Salicylic acid salts of salmeterol |
EP1429768B1 (de) | 2001-09-14 | 2016-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue arzneimittel zur inhalation |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
US6790856B2 (en) | 2002-01-31 | 2004-09-14 | Boehringer Ingelheim Pharma Kg | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
GB0202635D0 (en) | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
EP3536344B1 (en) | 2002-03-01 | 2020-02-19 | Chiesi Farmaceutici S.p.A. | Formoterol superfine formulation |
US6756508B2 (en) | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments |
DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
US7094788B2 (en) | 2002-04-13 | 2006-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions |
DE10216333A1 (de) | 2002-04-13 | 2003-10-30 | Boehringer Ingelheim Pharma | Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
BR0310084A (pt) | 2002-05-17 | 2005-02-15 | Novartis Ag | Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
US20040058950A1 (en) | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
CA2506949A1 (en) | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
DE10307759B3 (de) | 2003-02-19 | 2004-11-18 | Schering Ag | Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel |
EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
US20040184995A1 (en) | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
DE602004011494T2 (de) | 2003-03-28 | 2009-01-22 | Nycomed Gmbh | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen |
US20060189642A1 (en) | 2003-03-28 | 2006-08-24 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
US20050026886A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
US20050026887A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
EP1651270B1 (en) | 2003-07-29 | 2007-03-21 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising betamimetics and an anticholinergic |
AU2004262901B2 (en) | 2003-07-29 | 2010-05-13 | Boehringer Ingelheim International Gmbh | Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation |
JP2007500149A (ja) | 2003-07-29 | 2007-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患を治療するためのpdeiv阻害剤と抗コリン作用剤を含む薬剤 |
US20050026948A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
CA2534120C (en) | 2003-07-31 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
US20050025718A1 (en) | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
JP4700014B2 (ja) | 2004-02-06 | 2011-06-15 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 呼吸器系疾患の治療用の抗コリン作用薬及び4型ホスホジエステラーゼの組合せ剤 |
SI1713473T1 (sl) | 2004-02-06 | 2013-06-28 | Meda Pharma Gmbh & Co. Kg | Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB |
CN1905902A (zh) | 2004-02-06 | 2007-01-31 | Meda制药有限及两合公司 | 用于呼吸道疾病治疗的抗胆碱能药和β模拟药的新组合 |
US7712077B2 (en) * | 2004-02-27 | 2010-05-04 | International Business Machines Corporation | Method and system for instantiating components conforming to the “COM” specification in custom contexts |
ES2239546B1 (es) | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
DE102004016179A1 (de) | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
ES2317245T3 (es) | 2004-05-31 | 2009-04-16 | Laboratorios Almirall, S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
JP2008534611A (ja) | 2005-03-30 | 2008-08-28 | シェーリング コーポレイション | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 |
ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
US20100063016A1 (en) | 2007-02-19 | 2010-03-11 | Cipla Limited | Pharmaceutical Combinations |
MX2009008825A (es) | 2007-02-21 | 2009-10-12 | Almirall Sa | Nuevos metodos de terapia anticolinergica. |
WO2009004502A1 (en) | 2007-07-03 | 2009-01-08 | Nxp B.V. | Calibration of an amr sensor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
HRP20221034T1 (hr) | 2012-12-17 | 2022-11-11 | Almirall S.A. | Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća |
-
1999
- 1999-07-14 ES ES009901580A patent/ES2165768B1/es not_active Expired - Fee Related
-
2000
- 2000-07-07 CN CNB008127549A patent/CN1272334C/zh not_active Expired - Lifetime
- 2000-07-07 PT PT00951361T patent/PT1200431E/pt unknown
- 2000-07-07 UA UA2002010323A patent/UA73509C2/uk unknown
- 2000-07-07 EE EEP200200017A patent/EE04915B3/et active Protection Beyond IP Right Term
- 2000-07-07 RU RU2002103605A patent/RU2264401C3/ru active Protection Beyond IP Right Term
- 2000-07-07 DK DK00951361.5T patent/DK1200431T6/en active
- 2000-07-07 DE DE60001840A patent/DE60001840D1/de not_active Expired - Lifetime
- 2000-07-07 JP JP2001509727A patent/JP4030040B2/ja not_active Expired - Lifetime
- 2000-07-07 CN CNB2006100068921A patent/CN100451018C/zh not_active Expired - Lifetime
- 2000-07-07 HU HU0202100A patent/HU228594B1/hu active Protection Beyond IP Right Term
- 2000-07-07 AT AT00951361T patent/ATE235492T1/de active
- 2000-07-07 KR KR1020067027733A patent/KR100854321B1/ko not_active IP Right Cessation
- 2000-07-07 EP EP00951361.5A patent/EP1200431B3/en not_active Expired - Lifetime
- 2000-07-07 ES ES951361T patent/ES2193098T7/es active Active
- 2000-07-07 KR KR1020027000479A patent/KR100773844B1/ko not_active IP Right Cessation
- 2000-07-07 SK SK43-2002A patent/SK287480B6/sk not_active IP Right Cessation
- 2000-07-07 KR KR1020067027730A patent/KR100854315B1/ko active Protection Beyond IP Right Term
- 2000-07-07 DE DE60001840.7T patent/DE60001840T4/de not_active Expired - Lifetime
- 2000-07-07 CZ CZ2002-121A patent/CZ304292B6/cs unknown
- 2000-07-07 SI SI200030108T patent/SI1200431T1/xx unknown
- 2000-07-07 IL IL14753300A patent/IL147533A0/xx active Protection Beyond IP Right Term
- 2000-07-07 WO PCT/EP2000/006469 patent/WO2001004118A2/en active IP Right Grant
- 2000-07-07 CA CA2381165A patent/CA2381165C/en not_active Expired - Lifetime
- 2000-07-07 PL PL357160A patent/PL204024B1/pl not_active IP Right Cessation
- 2000-07-07 BR BRPI0012434A patent/BRPI0012434B8/pt not_active IP Right Cessation
- 2000-07-07 TR TR2002/00768T patent/TR200200768T2/xx unknown
- 2000-07-11 PE PE2000000691A patent/PE20010397A1/es not_active IP Right Cessation
- 2000-07-12 MY MYPI20003178 patent/MY126959A/en unknown
- 2000-07-12 EG EG20000907A patent/EG24066A/xx active
- 2000-07-12 TW TW089113865A patent/TWI284644B/zh active
- 2000-07-13 CO CO00052873A patent/CO5200759A1/es active IP Right Grant
- 2000-07-13 AR ARP000103613A patent/AR029760A1/es active IP Right Grant
- 2000-07-14 UY UY26244A patent/UY26244A1/es unknown
-
2002
- 2002-01-10 ZA ZA200200232A patent/ZA200200232B/xx unknown
- 2002-01-14 NO NO20020180A patent/NO329484B3/no not_active IP Right Cessation
- 2002-01-14 BG BG106301A patent/BG65565B1/bg unknown
- 2002-01-14 US US10/047,464 patent/US6750226B2/en not_active Expired - Lifetime
- 2002-05-29 HK HK02103992A patent/HK1042487B/xx not_active IP Right Cessation
-
2003
- 2003-12-17 US US10/740,264 patent/US7109210B2/en not_active Expired - Fee Related
-
2005
- 2005-04-28 US US11/116,777 patent/US7078412B2/en not_active Expired - Lifetime
- 2005-05-18 AU AU2005202144A patent/AU2005202144B2/en active Active
- 2005-07-06 RU RU2005121162/04A patent/RU2306312C2/ru active
- 2005-07-12 JP JP2005203365A patent/JP4951217B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-03 US US11/325,059 patent/US7196098B2/en not_active Expired - Lifetime
- 2006-12-08 US US11/636,181 patent/US7358260B2/en not_active Expired - Fee Related
-
2008
- 2008-03-07 US US12/074,929 patent/US7750023B2/en not_active Expired - Fee Related
-
2010
- 2010-05-26 US US12/787,772 patent/US7897617B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 US US13/011,131 patent/US8129405B2/en not_active Expired - Fee Related
- 2011-07-08 UY UY0001033494A patent/UY33494A/es not_active Application Discontinuation
-
2012
- 2012-01-20 US US13/354,873 patent/US8513279B2/en not_active Expired - Fee Related
-
2013
- 2013-01-03 BE BE2013C001C patent/BE2013C001I2/fr unknown
- 2013-01-07 CY CY2013001C patent/CY2013001I1/el unknown
- 2013-01-08 FR FR13C0001C patent/FR13C0001I2/fr active Active
- 2013-01-16 LU LU92132C patent/LU92132I2/fr unknown
- 2013-01-18 NO NO2013002C patent/NO2013002I2/no unknown
- 2013-07-11 US US13/939,742 patent/US8802699B2/en not_active Expired - Fee Related
-
2014
- 2014-06-20 US US14/311,102 patent/US9056100B2/en not_active Expired - Fee Related
-
2015
- 2015-05-14 US US14/712,866 patent/US9333195B2/en not_active Expired - Lifetime
-
2016
- 2016-02-09 US US15/019,009 patent/USRE46417E1/en active Active
- 2016-04-09 US US15/095,036 patent/US9687478B2/en not_active Expired - Fee Related
-
2017
- 2017-05-19 US US15/599,646 patent/US10034867B2/en not_active Expired - Fee Related
-
2018
- 2018-07-25 US US16/045,333 patent/US10588895B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102112474B (zh) * | 2008-08-08 | 2014-01-29 | 奇斯药制品公司 | 奎宁环碳酸酯衍生物及其药用组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1272334C (zh) | 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途 | |
CN1250545C (zh) | 新的奎宁环衍生物类及含有这类衍生物的药物组合物 | |
CN100338061C (zh) | 炔-芳基磷酸二酯酶-4抑制剂 | |
CN1293063C (zh) | 取代的杂环化合物、其制备方法和含有这些化合物的药物组合物 | |
CN1930158A (zh) | 新季铵化的奎宁环酯 | |
CN1298717C (zh) | 奎宁环氨基甲酸酯衍生物及其作为m3拮抗剂的应用 | |
CN1022488C (zh) | 抗毒蕈碱支气管扩张药丙酸3-奎宁环基酯的制备方法 | |
CN1678610A (zh) | 奎宁环酰胺衍生物 | |
CN1179945C (zh) | 吲哚衍生物、其制备方法及用途 | |
CN1291986C (zh) | 抗胆碱能剂,其制备方法及其作为药物的用途 | |
CN1662527A (zh) | 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物 | |
CN101056634A (zh) | 奎宁环衍生物及它们作为毒蕈碱m3受体拮抗剂的用途 | |
CN1268133A (zh) | 含有稠合环取代基的作为nos抑制剂的2-氨基吡啶 | |
CN1823068A (zh) | 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物 | |
CN1221534C (zh) | 取代的8-芳基喹啉磷酸二酯酶-4抑制剂 | |
CN1019113B (zh) | 3-芳氢基-3-取代的丙胺的制法 | |
CN1113236A (zh) | 非肽基速激肽受体拮抗剂 | |
CN1582285A (zh) | 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物 | |
CN1030415A (zh) | 饱和的杂环碳酰胺衍生物和它的制备方法 | |
CN1522249A (zh) | 作为神经肽y受体的配体的喹啉衍生物 | |
CN1444573A (zh) | 甲酰胺化合物及其作为人11cby受体拮抗剂的用途 | |
CN1910144A (zh) | 用于疾病治疗的磺胺衍生物 | |
CN1169792C (zh) | 取代的乙烯基吡啶衍生物和含有它们的药物 | |
CN1675206A (zh) | 奎宁环衍生物及含有相同化合物的药用组合物 | |
CN101080405A (zh) | 作为m3拮抗剂的季铵盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: OMIRO CO., LTD. Free format text: FORMER NAME: ALMILAR LABORATORY CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Spain Barcelona Patentee after: Almirall SA Address before: Spain Barcelona Patentee before: Laboratorios Almirall SA |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090114 |